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 Iodotyrosine deiodinase (IYD) catalyzes deiodination of mono- and diiodotyrosines (I-Tyr and 
I2-Tyr) to recycle iodide for proper thyroid function in mammals. IYD is also present in all animals 
and even some bacteria, although their function in lower organisms is not clear. In this study, a 
representative set of IYD from eukaryotes and prokaryotes was selected to assess their deiodination 
of iodophenols for bioremediation. Human IYD, bacterial IYD (hhIYD) and archaeal IYD 
(pfuIYD) exhibit different substrate binding recognition but their catalytic specificity is 
surprisingly conserved for iodotyrosines. Greater affinity of hhIYD for 2-iodophenol (2IP) 
compared to human IYD (~20 fold increased in affinity) indicated that interactions from the 
phenolate anion of 2IP can compensate for the lack of interactions established by the zwitterion of 
I-Tyr. Deiodination rates of 2IP by hhIYD are still very slow compared to that of I-Tyr suggesting 
that affinity is not diagnostic of catalytic efficiency. A crystal structure of hhIYDI-Tyr shows the 
formation of an active site lid induced by interactions with the zwitterion of I-Tyr. However, the 
active site lid is not ordered in a structure of hhIYD2IP indicating that 2IP cannot trigger closure 
of the active site lid. Reduction of hhIYD in the alternative presence of a substrate analog F-Tyr 
and 2IP also indicates differences in the ability of the zwitterionic substrate and 2IP to initiate IYD 
catalysis. A flavin semiquinone (FMNsq) was detected during the reduction of hhIYD in the 
presence of F-Tyr but accumulation of this same intermediate was not observed in the presence of 
2IP. Crystallographic and redox studies demonstrated that 2IP lacks an ability to initiate formation 
of the active site lid and cannot stabilize the one-electron chemistry for IYD catalysis, which 
explain its slow deiodination rates. 
 To enable IYD for bioremediation of iodophenols, three hhIYD mutants were generated in 
hopes of improving the kcat/Km values for iodophenol turnover. However, these mutants did not 
provide much increase in the catalytic efficiency for deiodination of iodopehnols as their kcat/Km 
values are ~3 – 17 fold lower than that of the wild-type hhIYD. However, the studies demonstrated 
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a repulsive interaction between Glu91 and the carboxylate of 4-hydroxy-3-iodobenzoate 
(2IPCOOH) can significantly increase the Km for deiodination of 2IPCOOH. Removal of this 
repulsive interaction can significantly decrease the Km as evident by a ~4 fold lower Km for 
deiodination of 2IPCOOH by an E91R mutant compared to the wild type. This result suggests E91 
is a potential mutation site for fine-tuning the Km for deiodination of iodophenols. 
 In addition to hhIYD, two IYD-related enzymes (BluB and 3EO8) were selected to examine 
their native affinity for 2IP. Neither BluB nor 3EO8 bound 2IP with measurable affinity. Further 
structural analysis of 3EO8 indicated that its active site was relatively small to accommodate 2IP. 
3EO8 mutants were therefore generated to enlarge its active site for 2IP coordination. However, 
the 3EO8 mutants did not improve the affinity for 2IP. A mutant with the highest affinity with 2IP 
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Chapter 1: Introduction 
1.1 Halogenated aromatics: Significance, concerns and biological remediation 
 Bioremediation is the use of microorganisms and enzymes to degrade environmental pollutants.1 
This process was initially developed through defense mechanisms of microorganisms thriving in 
contaminated sites. Halogenated compounds present in nature allow microorganisms to evolve their 
metabolic pathways to use organohalides as a new carbon and energy source.2 Several anaerobic 
bacteria are able to consume chlorinated benzenes3 or polychlorinated dibenzodioxins4 as terminal 
electron acceptors for their energy metabolism. These bacteria utilize reductive dehalogenation for 
their electron transport process.5 Development of microbial strains has been done for implementing 
detoxification of halogenated wastes. As bioremediation involves enzymatic processes, it is 
normally operated at neutral pH and mild temperature without producing more toxic wastes.2, 6 
Lately, bioremediation has been developed to rival the efficiency of chemical treatments but offers 
a more environment-friendly alternative.6 For example, a lignin peroxidase from Phanerochaete 
chrysosporiumhas  has been used for bioremediation of polycyclic aromatic hydrocarbons (PAHs), 
which provides similar product ratios to those found from chemical degradation.6 However, certain 
classes of substances are resistant to biodegradation, and thus discourage application of biological 
processes. Among the most problematic non-biodegradable compounds are haloaromatics because 
the halogens may block many dioxygenase enzymes which normally initiates degradation of 
aromatic rings.2, 7-9 Haloaromatics are used in many applications such as polychlorinated biphenyls 
(PCBs) used in electrical transformers, coolants and hydraulic fluids,2, 7 pentachlorophenol (PCP) 
used as pesticides2, 7, 10 and dichlorodiphenyltrichloroethane (DDT) used commonly as pesticide 
(Figure 1-1).2, 7 Large-scale consumption coupled with poor disposal practice of halogenated 
aromatics have liberated a large amount of these compounds into the environment. Their 
persistence together with intrinsic toxicity consequently harm the surroundings and human health.2, 
7-9 Many efforts have been directed at replacing haloaromatics with other less harmful materials. 
However, the unique physiochemical properties of halogenated compounds dim the feasibility.2 
2 
 
Accordingly, research is currently directed at eliminating non-biodegradable halogenated 
aromatics, especially, the most widely-used chlorinated ones.2, 7-9 Development of new enzymes to 
eliminate different classes of non-biodegradable substances would provide more alternatives and 
enhance the efficiency of bioremediation. Studies on degradation of haloaromatic compounds by 
microorganisms have led to discovery and characterization of several dehalogenases that play key 






Figure 1-1.  Structures of (A) polychlorinated biphenyls, PCB (B) pentachlorophenol, PCP and (C) 
dichlorodiphenyltrichloroethane, DDT. 
 
1.2 Types of aromatic dehalogenases 
 There are three classes of aromatic dehalogenases that have different mechanisms and different 
net reactions. 2, 7  Examples below are aromatic dechlorinating enzymes as they are the best studied 
for bioremediation. 
 1.2.1 Hydrolytic dehalogenases 
 Hydrolytic dehalogenases catalyze replacement of halide with a hydroxyl group.2, 7  An example 
is 4-chlorobenzoyl CoA dehalogenase found in a number of aerobic soil bacteria catalyzing 
dechlorination of 4-chlorobenzoyl CoA, an intermediate formed in certain PCB degradation 
pathways.2, 11  The mechanism for catalysis involves nucleophilic aromatic substitution, which is 
normally unfavorable due to the introduction of a nucleophile to an electron-rich aromatic ring. 
However, with a para electron-withdrawing thioester group in the substrate, 4-chlorobenzoyl CoA 
dehalogenase can mediate catalysis by delocalizing electrons from an attacking Asp-145 into 
thioester prior to expulsion of chloride (Figure 1-2).  A catalytic cycle is then completed by 
hydrolysis of an acyl-enzyme intermediate complex.  The mechanism shows 4-chlorobenzoyl CoA 
3 
 
dehalogenase requires the substrate to contain a thioester group at the para position of a 

















Figure 1-2. Mechanism of 4-chlorobenzoyl CoA dehalogenase. 
 
1.2.2 Oxidative dehalogenases 
 Oxidative dehalogenases catalyze replacement of a halide with a hydroxyl group derived from 
molecular oxygen.2, 7  An example is pentachlorophenol monooxygenase (PCP monooxygenase), 
containing flavin adenine dinucleotide (FAD) as a cofactor.7  PCP monooxygenase catalyzes the 
first step of PCP degradation, which transforms PCP to tetrachlorohydroquinone (TCHQ) in the 



























Figure 1-3. (A) Degradation of PCP to TCHQ by PCP monooxygenase (B) Proposed 
mechanism of PCP monooxygenase. 
 
 The mechanism illustrated in Figure 1-3B shows that PCP monooxygenase requires a substrate 
(PCP) to have a para-hydroxyl group to mediate hydroxylation.  The para-hydroxyl substituent 
helps with bond reorganization to react with the C)4a(hydroperoxy-FAD to produce tetrachloro-
1,4-benzoquinone (TCBQ). This product is then reduced by NADPH to yield TCHQ.2  This 
observation suggests PCP monooxygenase is applicable for a substrate with a different substituted 





 1.2.3 Reductive dehydrogenases 
 Reductive dehydrogenases replace a halosubstituent with a hydrogen atom.2, 7  An example is 
tetrachlorohydroquinone dehydrogenase (TCHQ dehydrogenase), which catalyzes reductive 
dechlorination of TCHQ to trichlorohydroquinone (TriCHQ). This is the second step in a PCP 
degradation pathway and uses glutathione (GSH) as a reducing equivalent.2, 7 The proposed 
mechanism in Figure 1-4 shows chloride is removed during transformation of TCHQ to 
trichlobenzoquinone (TriCBQ), suggesting necessity for the presence of two para-hydroxyl groups 
in the substrate for dechlorination.  TriCBQ then undergoes 1,4-nucleophilic addition with GSH 
and is reduced by Cys-13 in an active site of the enzyme to yield TriCHQ as a product.  A catalytic 
cycle is completed by oxidation of another GSH to exchange a disulfide bond with a mixed 













Figure 1-4. Proposed mechanism of reductive dechlorination of TCHQ by TCHQ 
dehaloganase. 
 
 As illustrated in three mechanisms above, each enzyme requires substrates with different groups 
and/or different substituent positions. Additional mechanisms of dehalogenases may provide 
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additional alternatives for detoxification of the halogenated aromatics. For example, an 
iodotyrosine deiodinase (IYD) may be used in bioremediation of haloaromatics. 
1.3 Introduction to iodotyrosine deiodinase (IYD) 
 IYD is a dimeric flavoprotein responsible for recycling iodide from the byproducts of thyroid 
hormone biosynthesis, monoiodotyrosine (I-Tyr) and diiodotyrosine (I2-Tyr) (Figure 1-5), which 
otherwise would be liberated as waste.13, 14  Iodide is a micronutrient essential for production of 
thyroid hormones (THs) (Figure 1-5), which play important roles in development during early 
childhood and control of metabolism in adults.15, 16  The recommended intake of iodide is relatively 
small (150 µg per day),16 but IYD is crucial to recycle iodide to ensure a sufficient amount of iodide 
for TH synthesis. Mutations of the IYD gene have shown evidence of serious birth deficiency, 









Figure 1-5. Structures of monoiodotyrosine (I-Tyr) and diiodotyrosine (I2-Tyr) along with thyroid 
hormones T3 and T4. 
 
 IYD reduces a C-X bond of I-Tyr and I2-Tyr using a flavin mononucleotide (FMN) cofactor 
(Figure 1-6).13, 14 This reductive dehalogenation is very rare in aerobic organisms. Iodothyronine 
deiodinase (ID) is the only one other enzyme that catalyzes a similar reaction during its catalytic 
deiodination of THs (Figure 1-5).18 IYD and ID have quite different evolutionary origins and 
mechanisms. ID is in the thioredoxin superfamily19 while IYD belongs to the nitro-FMN reductase 
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superfamily (previously known as the NADH oxidase/Flavin reductase superfamily).20 
Deiodination performed by ID relies on an active site selenocysteine in contrast to IYD that uses 












Figure 1-6. (A) Reductive deiodination of I-Tyr and I2-Tyr by IYD. (B) Structures of 2IP and I-
Tyr. 
 
 IYD intrigued us to study this enzyme for bioremediation of halogenated aromatic compounds 
as it has similar activity as reductive dehalogenases. However, an advantage of IYD over some 
reductive dehalogenases is it is oxygen stable in contrast to cobalamin-dependent reductive 
dehalogenases, which are oxygen sensitive.21 A structure of an IYD substrate, I-Tyr, includes a 
subcomponent of 2-iodophenol. These properties of IYD raise the propensity of engineering IYD 
to accept halophenols as new substrates. Moreover, previous studies reported the ability of IYD to 
promote debromination and dechlorination of bromo- and chlorotyrosine.22, 23 This finding 
broadens the possibility of developing a modified engineered IYD to detoxify the most problematic 
chlorinated aromatic compounds. Furthermore, IYD catalyzes substrates with a hydroxyl group 
ortho to the C–I bond, which offers a different regiochemistry from the three dehalogenases 
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described above. Hence, success of IYD engineering would provide alternative catalytic machinery 
to perform dehalogenation of a different substrate architecture. 
1.4 Challenges of engineering nIYD to perform dehalogenation of halophenols 
 Crystal structures of mouse IYD demonstrate that IYD exists as a homodimer with FMN bound 
at the interface (Figure 1-7 A).24 The zwitterion of I-Tyr is key to induce formation of an active site 
lid, which is disordered in the absence of I-Tyr (Figure 1-7 ).24 The ordering of the lid is caused by 
bridging between the zwitterion of I-Tyr and three residues in the active site lid (Glu153, Tyr157 
and Lys178) and FMN (Figure 1-8).24 Besides, these electrostatic interactions from the zwitterion 
of I-Tyr, the co-crystal complex is likely to be stabilized by -stacking between an aromatic ring 
of I-Tyr and FMN, hydrogen bonding of the phenolate of I-Tyr to an amide backbone of Ala126 













Figure 1-7. Crystal structure of (A) mouse IYD (PDB 3GB5) and (B) mouse IYD with I-Tyr (PDB 
3GFD). An active site lid consists of C-terminus of αC and αD helices. Two different shades of 





























Figure 1-8. Active site of mouse IYD with I-Tyr. Two different shades of blue represent two 
individual polypeptides. FMN and I-Tyr are presented in yellow and blue (carbon atoms) 
respectively. Black dashed lines represent hydrogen bonding within 2.4 – 3.1 Å. 
  
 Site-directed mutagenesis of each active site lid residue confirmed the importance of the 
zwitterion of the substrate for binding and catalysis. Studies on two mutants mouse IYD, E153Q 
and Y157F, demonstrated decreases in both binding affinity and catalytic efficiency (kcat/Km). 
E153Q has an undetectable level of both affinity to I-Tyr and a deiodination of I2-Tyr.25 The results 
correspond to recent binding and kinetic studies of IYD from Drosophila.23 Previous studies have 
raised the challenges for engineering IYD for deiodination of 2IP as it lacks the zwitterion to 
stabilize the lid as well as to mediate IYD binding and catalysis. 
1.5 Specific aims 
 The ultimate goal for this study is to engineer IYD for deiodination of iodophenols. As a prelude 
to IYD engineering, the basal binding and catalysis of IYD for iodophenols were studied. My first 
research objective was to investigate basal binding and catalysis of IYD with iodophenols 
compared to that of I-Tyr to learn how the absence of the zwitterion affects binding and catalysis.  
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My second objective was to engineer IYD and an IYD-related enzyme within the nitro-FMN 
reductase superfamily to accept iodophenols as a substrate. This dissertation describes the 
following. First, an IYD homolog from bacterium, Haliscomenobacter hydrossis, (hhIYD) was 
selected for engineering IYD for deiodination of iodophenols by performing binding and catalytic 
activity of a representative set of three IYDs from eukaryotes and prokaryotes with 2IP and I-Tyr. 
Second, binding and catalytic activity of a set of 2-iodophenol derivatives were studied to establish 
a correlation between substrate binding affinity and catalysis. Third, crystallographic studies of 
hhIYD in the alternative presence of I-Tyr and 2IP were pursued to compare coordination of I-Tyr 
and 2IP to hhIYD, which explains slow deiodination of 2IP. Fourth, three hhIYD mutants were 
generated using rational designs based on a predicted structure of hhIYD aiming to improve 
catalytic efficiency (kcat/Km) for deiodination of 2IP and 4-hydroxy-3-iodobenzoic acid 
(2IPCOOH). Fifth, binding affinity of 2IP with two IYD-related enzymes in the nitro-FMN 
reductase superfamily (BluB and 3EO8) and eight 3EO8 mutants was measured to assess 















Chapter 2: Analysis of binding and catalysis specificity for IYD homologs 
 2.1 Introduction 
 The discovery that IYD is pervasive throughout metazoan and some prokaryotes has raised a 
question, what are the functions of IYD in organisms without thyroid hormones. Examples are 
prokaryotic IYDs found in bacteria and those found in even more primitive organisms like archaea. 
Their functions are still unknown although there is evidence that a few bacterial strains accumulate 
iodide.26 IYD is likely involved in catabolism or detoxification allowing bacteria and archaea to 
survive environments containing toxic halogenated compounds. This implies bacterial and archaeal 
IYD may not have I-Tyr or I2-Tyr as their primary substrates. Hence, IYD from bacteria and archaea 
may exhibit substrate promiscuity that may enable IYD to function in bioremediation. 
 Three IYD homologs were selected to study substrate binding and catalysis specificity of IYD 
from eukaryotes and prokaryotes. Human IYD was chosen as a representative from eukaryotes. 
IYDs from the bacterium, Haliscomenobacter hydrossis, (hhIYD) and a hyperthermophilic 
archaea, Pyrococcus furiosus (pfuIYD), were selected as representatives of IYDs from prokaryotes. 
In addition, H. hydrossis is commonly found in waste water after sewage treatment.27 Hence, its 
function may be related to dehalogenation of halogenated pollutants. The pfuIYD has an advantage 
over other homologs as it can function at high temperature at which increased catalytic activity can 
be expected. As discussed below, pfuIYD may display some level of substrate promiscuity based 
on sequence alignment and phylogenetic analysis. 
 IYD is a subclass within the nitro-FMN reductase superfamily that also includes other 
subclasses such as NADH oxidase (NOX) and flavin reductase P (FRP). The structure of mouse 
IYD shows most structural similarity to a bacterial flavin destructase (BluB) responsible for 
biosynthesis of a lower ligand for vitamin B12.24, 28 As IYD and BluB share a unique active site lid 
position different from NOX and FRP, they were categorized as a new subclass in the 
superfamily.24, 28 Sequence analysis of mammalian IYDs exhibited an N-terminal membrane 
anchor, an intermediate domain and a catalytic domain.29 The first two domains show higher 
12 
 
variability and lack homology to known protein domains while the catalytic domain is more 
conserved and shows homology to members of the nitro-FMN reductase superfamily.20, 30 Fewer 
domains were found in hhIYD, which lacks the predicted membrane anchor while pfuIYD 
expressed only the catalytic domain.31 Sequence alignment of catalytic domains of mammalian 
IYDs, hhIYD and pfuIYD reveals that hhIYD and pfuIYD still contain the three active site lid 
residues (Glu153, Tyr157, Lys178 of mouse IYD) and Thr interacting with O4 and N5 of the FMN 
cofactor (Thr235 of mouse IYD), which are excellent predictors for deiodinase activity (Figure 2-
1).30, 31 Both prokaryotic IYDs also have conserved FMN binding residues except for Lys11 of 
pfuIYD, which substitutes a conserved Arg. This change may explain the weak affinity of FMN in 
pfuIYD as discussed in a result session. In addition, phylogenetic sequence analysis of IYD and 
other members in the superfamily also implied that pfuIYD may exhibit more substrate promiscuity 
as its position on the phylogenetic tree is distant from IYD homologs, but closer to other enzymes 
















































Figure 2-1. Sequence alignment of the catalytic domains of mouse IYD, human IYD, hhIYD and 
pfuIYD. Numbers on the left and right indicate numbering for amino acid residues. Residues in red 
and white are fully conserved. FMN and substrate coordinating residues are indicated with (+) and 
(*), respectively. Columns highlighted in red indicate residues that coordinate with the substrate 
zwitterion. A column highlighted in yellow indicates a residue that coordinates with the O4 and N5 
positions of the FMN cofactor. The figure was modified from that created by Dr. Abhishek V 















Figure 2-2. Phylogenetic analysis of the IYD branch of the nitro-FMN reductase superfamily. The 
figure is adapted from the literature.30 The branch lengths are proportional to the number of amino 
acid substitutions per aligned residue. IYD from P. furiosus (pfuIYD) is circled in red. 
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 This Chapter describes specificity of substrate recognition and turnover for three different IYD 
homologs using 2-iodophenol (2IP) and mono-iodotyrosine (I-Tyr) as substrates. 2IP was selected 
because it is a representative of haloaromatics and has the most structural similarity to I-Tyr. The 
C–I bond is the weakest carbon-halide bond, hence is the easiest C–X bond to cleave. In addition, 
both 2IP and I-Tyr are mono-iodinated compounds, which reduce complexity for product analysis 
(compared with diiodophenol and I2-Tyr). Further investigations on binding and catalysis of 
halotyrosine and halophenol derivatives were performed to study the correlation between an active 
site binding and deiodinase activity. 
2.2 Experimental Procedures 
2.2.1 Materials 
 Expression plasmids (pSMT3) containing human IYD and hhIYD genes (pSMT3-His6-SUMO-
IYD-His6) were kindly provided by former graduate students, Dr. Jimin Hu32 and Dr. Jennifer 
Buss,33 respectively. The pfuIYD expression plasmid (pET24a-pfuIYD-His6) was kindly provided 
by another former graduate student, Dr. Abhishek V Phatarphekar.31 The SUMO specific protease 
Ulp1 expression plasmid (pET28b-Ulp1) was kindly provided by Dr. C. Lima (Memorial Sloan-
Kettering Institute, New York, NY). All expression plasmids containing IYD genes are under the 
T7 promoter, hence IPTG was used to induce protein expression. All DNA primers were 
synthesized by IDT (Coralville, IA). The pET24a plasmid and Rosetta 2 DE3 E. coli cells were 
purchased from Novagen (Darmstadt, Germany). Electrocompetent Genehogs (E. coli) cells were 
obtained from Invitrogen (Carlsbad, CA). Pfu Turbo polymerase and its buffer were obtained from 
Agilent (Santa Clara, CA). T4 DNA ligase, all restriction enzymes and their buffers were purchased 
from New England BioLabs Inc. (NEB) (Ipswich, MA). PageRuler broad range unstained protein 
standards, GeneRuler 1 Kb plus DNA standards, Genejet plasmid miniprep kit, His-Pur Ni-NTA 
resin and ScintiSafe Plus 50% scintillation cocktail were obtained from Thermo Fisher Scientific 
(Waltham, MA). QIAquick gel extraction kit was purchased from QIAGEN. The Sephacryl S-200 
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HR resin for size exclusion chromatography (SEC) was obtained from GE Healthcare (Piscataway, 
NJ).  
 Reagents of the highest grade available were used without purification. 3-Bromo-L-tyrosine was 
purchased from AEchem Scientific Corporation (Naperville, IL). 3-Chloro-L-tyrosine (Cl-Tyr), 
3,5-diiodo-L-tyrosine (I2-Tyr), 2-bromophenol (2BP), 4-aminophenol, 4-amino-2-iodophenol 
(4A2IP) and 4-cyanophenol were obtained from Sigma-Aldrich (Madison, WI). 3-Fluoro-L-
tyrosine (F-Tyr) was purchased from Astatech, Inc (Bristol, PA). Formic acid (88%), 3-iodo-L-
tyrosine (I-Tyr), 2-iodophenol (2IP) and m-cresol were obtained from Acros Organics (Morris 
Plains, NJ). 2-Chlorophenol (2CP), 2-fluorophenol (2FP) and 4-hydroxylbenzoic acid were 
purchased from Alfa Aesar (Tewksbury, MA). 4-Hydroxy-3-iodobenzonitrile (2IPCN) was 
purchased from Pharmabridge, Inc (Doylestown, PA). Benzoic acid was obtained from 
Mallinckrodt Chemical Work (St. Louis, MO). 
2.2.2 General methods 
 Plasmids were purified from cultures grown from selected single colonies of Genehogs E. coli 
cells using the Genejet plasmid miniprep kit. All PCR reactions were performed using an Eppendorf 
Mastercycler gradient (Hauppauge, NY). E. coli cells were transformed with the plasmid of interest 
using an Eppendrof Eporator at 2500 V. Restriction digestion reactions for all PCR products and 
plasmids were performed at 37oC for 1 h. The digested PCR products and linearized plasmids were 
purified and visualized through 1% agarose gel electrophoresis operated at 100 V for 50 min. The 
digested products were extracted from agarose gels using the QIAquick gel extraction kit 
(QIAGEN). Ligation reactions were carried out using T4 DNA ligase.  
 Purification of all IYDs was carried out with Ni2+ column chromatography (a flow rate of 1 
ml/min) and size exclusion chromatography (a flow rate of 0.3-0.4 ml/min) using an AKTA Prime 
FPLC (GE Healthcare). Centrifugation steps were performed using the Beckman Coulter 
centrifuge. Protein concentration was performed using Amicon Ultra-15 centrifugal filter with 10 
kDa MW cut off (Millipore). Proteins were analyzed by SDS-PAGE (12% resolving and 5% 
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stacking acrylamide layers) at 220 V for 45 min. The ε280, theoretical pI and molecular weight of 
purified IYD homologs were determined from their amino acid sequences using ExPASy 
ProtParam.34 All UV measurements were performed by a Hewlett-Packard 8453 
spectrophotometer. For pfuIYD, protein concentration was determined from the A280 after 
subtracting an absorbance contributed from free FMN at 280 nm, using A280/A450 = 1.57 for 
calculation30 and the FMN occupancy per enzyme active site was determined by measuring the 
absorbance of FMN at 450 nm (ε450 [FMN] = 12,500 M-1 cm-1).35 The A280/A450 and extinction 
coefficients of FMN inside IYD at 450 nm (ε450 [IYD]) for human IYD and hhIYD were determined 
and used to calculate their protein concentration and FMN occupancy. To determine A280/A450 of 
FMN and ε450 [IYD], IYD was diluted in 100 mM potassium phosphate, pH 7.4 to contain at least 
~80 µM of FMN (200 µl). The solution was separated into two equal aliquots. One of the aliquots 
was used to extract free FMN from the FMN-bound protein through heat denaturation (110 oC for 
10 min). The heated solution was cooled to room temperature and centrifuged for 3 – 5 min to 
remove precipitated and denatured protein. The supernatant was then loaded on the Ni2+ affinity 
column (0.2 – 0.3 ml) to retain soluble IYD on the Ni2+ resin. Free FMN was eluted using the same 
potassium phosphate buffer. The concentration of free FMN was determined (ε450 [FMN] = 12,500 M-
1 cm-1). Then, the ε450 [IYD] was calculated using the concentration of free FMN and A450 of the nature 
protein. The concentration of IYD was calculated using A280 after correcting with a dilution factor 
created by eluting the FMN. Protein concentration of human IHD and hhIYD was determined from 
the A280 after subtracting an absorbance contributed from free FMN at 280 nm, using A280/A450 = 
1.9 ± 0.1 (human IYD) and 1.72 ± 0.04 (hhIYD) for calculation. The FMN occupancy per enzyme 
active site was determined by measuring the absorbance of FMN at 450 nm (ε450 [human IYD] = 13,000 
± 300 M-1cm-1 and ε450 [hhIYD] = 13,600 ± 300 M-1cm-1). Enzyme concentration used for each 





2.2.3 Cloning of hhIYD 
 An hhIYD construct without a SUMO fusion was generated to optimize purity of hhIYD for 
protein crystallization. The hhIYD gene was amplified from the pSMT3 construct containing an 
hhIYD-SUMO fusion using the recommended concentration of Pfu Turbo polymerase as suggested 
by the manufacturer. A forward primer 5’-AATTAATCATATGAAGCAAAAGCCTGCTT-3’ and 
a reverse primer 5’-AATTAATCTCGAGCTAGTGATGGTGATG-3’containing NdeI and XhoI 
restriction sites (underlined) were used for gene amplification. The hhIYD gene was subcloned 
using the NdeI and XhoI sites into the pET24a vector for expression without the SUMO fusion. 
2.2.4 Site-directed mutagenesis 
 The pET24a-pfuIYD-His6 was used as a template for site-directed mutagenesis and Pfu turbo 
polymerase was used for amplification. K11R was introduced by the forward primer 5'-
GCCAAACGTCGTCGCACTGTTCGCAAA -3' and its reverse complement. The mutated codon 
is indicated in red. Amplification of the mutated plasmid was confirmed through 1% agarose gel 
electrophoresis before transformation into electrocompetent Genehogs E. coli cells (Invitrogen). 
The plasmid was purified from a culture grown from the selected single colonies and the mutation 
was confirmed by DNA sequencing (Genwiz). 
2.2.5 Expression and purification of IYD homologs 
 Human IYD without its N-terminal transmembrane sequence (residues 2-31) was expressed 
with a SUMO fusion as described previously.32 hhIYD and pfuIYD were expressed without a 
SUMO fusion in its full-length native sequence.31 Rosetta 2 (DE3) E. coli cells were transformed 
with the plasmid containing the IYD gene of interest. Single colonies were picked and inoculated 
into a small culture of Luria-Bertani media (LB) (25 ml) containing kanamycin (50 µg/ml) and 
chloramphenicol (34 µg/ml). The culture was incubated with shaking for 14-16 h at 37 oC. The 
small culture was then diluted by approximately 50-fold into a culture of LB medium (1 L) with 
the same concentration of the antibiotics described above and incubated with shaking at 37 oC until 
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OD600 of 0.6-0.8 was obtained. Riboflavin (10 µM) was supplemented in the 1 L culture of media 
containing IYD when their FMN occupancy is low (≤ 60 %) in attempt to increase the FMN 
occupancy of the final protein. Protein expression was performed by addition of IPTG (20 µM) and 
incubation with shaking at 16 oC for 12 – 14 h.31 Cells were harvested by centrifugation (5000 xg 
for 10 min) and either were used for purification right away or frozen in liquid nitrogen and stored 
at -80 oC.   
 For IYD purification, cells were resuspended in lysis buffer (500 M NaCl, 25 mM imidazole, 
10% glycerol, 0.5 mM TCEP and 50 mM sodium phosphate, pH 7.9) and supplemented with FMN 
(100 µM). The cells were then lyzed by passage through a French press at a pressure of 1,000 psi 
or an Emulsiflex C3 homogenizer (Avestin) (Ottawa, ON, Canada) at a pressure of 20,000 psi for 
3 – 4 times. Cell lysates were centrifuged at 45,000 x g for 0.5 – 1 h to precipitate cell debris. With 
one trial, cell lysates containing pfuIYD were heated at 80 oC for 20 min and cooled to room 
temperature prior to centrifugation with an aim to increase FMN occupancy of the pfuIYD. Both 
SUMO-IYD and non-SUMO tagged IYD was purified in two steps using Ni-NTA affinity and size-
exclusion chromatography (SEC). The supernatant (25 – 35 ml) was first introduced onto a Ni-
NTA column (10 ml) that was pre-equilibrated with lysis buffer (3 column volumes). The loaded 
sample was washed with lysis buffer containing 25 mM, 60 mM and 100 mM imidazole for 2 – 4 
column volumes each. IYD was then eluted with lysis buffer containing 300 mM imidazole. The 
purified SUMO-IYD protein were incubated with Ulp1 (approximately, 1:100 w/w for 10-12 h) for 
12 – 14 h at 4 oC for SUMO lysis. The protein solution was concentrated using an Amicon Ultra-
15 centrifugal filter (10 kDa MW-cut off, Millipore) until reaching a volume of ~ 1 ml.  
 Both SUMO-IYD and non-SUMO tagged IYD solutions were supplemented with FMN (100 µl 
of 10 mM FMN) before applying to a size-exclusion column (volume = 220 ml), pre-equilibrated 
with buffer (300 M NaCl, 15% glycerol, 0.5 mM TCEP and 50 mM sodium phosphate, pH 7.4). 
Fractions with desired protein were collected and analyzed by SDS-PAGE. Note that the final 
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buffer used for pfuIYD was maintained at pH 6.8 to avoid a possibility of protein precipitation due 
to zero net charge on the protein (pI = 7.8). 
2.2.6 Synthesis of 4-hydroxy-3-iodobenzoic acid (2IPCOOH) 
 4-Hydroxybenzoic acid (830 mg, 6.0 mmol) was dissolved in conc. NH4OH solution (29% w/w, 
100 ml) and stirred at 4 oC. Iodine (1.5 g, 6.0 mmol) in EtOH (18 ml) was added dropwise over 1 
h and the mixture was stirred for another 2.5 h at 4 oC. The mixture was rotoevaporated to a volume 
of 40 ml and then acidified to pH 2 using HCl (1 N). The mixture was further rotoevaporated until 
dry. The solid was dissolved in EtOAc (20 ml), washed twice with H2O (20 ml). The organic phase 
was rotoevaporated again to yield pale yellow solid. The solid was dissolved in 20% aq. acetonitrile 
with 0.44% formic acid (v/v) and purified by reverse-phase HPLC (Econosphere C18 column; 250 
x 10 mm, 10 μm) using a gradient of 20 – 30% of aq. acetonitrile with 0.44 % (v/v) formic acid 
over 15 min at a flow rate of 5 ml/min. Fractions containing the product (tR = 6.8 min) were 
lyophilized to yield 2IPCOOH as a white solid (360 mg, 23 % yield). 1H NMR (400 MHz, acetone-
d6) δ 7.05 (d, 1H, J = 8.4 Hz), 7.92 (dd, 1H, J = 2.0, 8.5 Hz), 8.40 (d, 1H, J = 2.0 Hz) (Appendix 
Figure A1); 13C NMR (101 MHz, acetone-d6) δ 82.90, 114.5, 123.8, 131.6, 141.2, 160.7, 165.4 
(Appendix Figure A2). Both the 1H and 13C NMR spectra are consistent with the literature.36  
2.2.7 Catalytic activity assay with 125I-[I2-Tyr] 
 Deiodination rates of I2-Tyr by IYD were determined by quantifying the release of [125I]-iodide 
from the radiolabeled 125I-[I2-Tyr] as previously described.20, 37 In brief, reaction mixtures contained 
200 mM KCl, 50 mM 2-mercaptoethanol, 0.05 mM methimazole and 0.033 mM FMN, 100 mM 
potassium phosphate pH 7.4, I2-Tyr and the indicated enzyme concentrations. The 125I-[I2-Tyr] was 
added to each reaction mixture (15,000-20,000 cpm). The reactions were then initiated by addition 
of 10% sodium dithionite in 5% sodium bicarbonate (100 µl) to reach a final volume of 1 ml. The 
reactions were conducted at 25 oC and quenched by addition of 0.1% I2-Tyr in 0.1 N NaOH (100 
µl). An aliquot from each reaction (850 μl) was applied onto a column containing AG 50W-X8 
cation exchange resin (Bio-Rad Labs), which was pre-equilibrated with 10% acetic acid. The 
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column was eluted with 4.15 ml of 10% acetic acid and the eluate was collected in a scintillation 
vial (fraction A). The column was further washed with 5 ml of 10% acetic acid and the eluate was 
collected in another scintillation vial (fraction B). The rest of the reaction mixture (250 μl) was 
transferred to a new scintillation vial containing 4.75 ml of 10% acetic acid (fraction S). Fraction 
A, B and S were then added with scintillation cocktail (10-12 ml) and the radioactivity (cpm) of 
each fraction was measured using a Tri-Carb 2910TR liquid scintillation counter (Perkin Elmer). 
The released radioactive iodide (F) was determined from equation 2-1.37 The initial rate (V) was 
determined from equation 2-237 (F0 = background radioactivity from a control reaction without 
enzyme). The initial rates (nmol h-1) were then fit against substrate concentrations (S, µM) into the 
Michaelis-Menten equation 2-3 using Origin 6.0. 
F =  




                                                                                                           Equation 2 − 1 
 
V = (F − F0) × (2 × 
1
time (min)
  ×  
60 min
1 h
× [S])                                                  Equation 2 − 2 
 
V =  
Vmax [S]
Km + [S]  
                                                                                                                     Equation 2 − 3   
2.2.8 Binding affinity determination 
 Binding affinity for ligands of IYD was determined by their ability to quench the fluorescence 
of the oxidized FMN (FMNox) in the active site of IYD (λex = 450 nm and λem = 523 nm) as 
previously described.22, 32 The fluorescence signal was measured using a Fluoromax-4 fluorescence 
spectrophotometer (Horiba Scientific). IYD in 100 mM potassium phosphate, pH 7.4 (pH 6.9 for 
pfuIYD) was stirred for 15 – 30 min prior to ligand addition (See Figure 2-4, 2-5 and Appendix 
Figure A7 for more details). Binding affinity was monitored over 4 log concentration units, 
centered at the concentration that provides 50% fluorescence quenching. Observed fluorescence 
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intensities (F) were divided with an initial fluorescence signal without addition of ligand (F0). The 
ratios of F/F0 were then plotted against log units of ligand concentrations (S0). The dissociation 
constant (Kd) values were determined by non-linear least squares fitting of the data to equation 2 – 
438 using Origin 6.0. ∆F is the total change in fluorescence intensity and E0 is enzyme concentration. 
F
F0




(Kd  +  E0  + S0) −  √(Kd  +  E0 +  S0)
2 − 4E0S0
2E0
)                      Equation 2 − 4 
2.2.9 Catalytic dehalogenation of mono-halogenated compounds by IYDs 
 Catalytic turnover of IYD for mono-halogenated compounds was observed by quantifying the 
product of dehalogenation after separation by reverse-phase HPLC as previously described.23, 31 In 
brief, mono-halogenated substrates were incubated with IYD in 111 mM potassium phosphate pH 
7.4 (900 µl) (unless specified otherwise) and the reaction was initiated by addition of 5% dithionite 
in 5% sodium bicarbonate (100 µl). This mixture was incubated at 25 oC (unless specified 
otherwise) prior to quenching with 88% formic acid (50 µl). An internal standard (IS) of either m-
cresol or benzoic acid was used to quantify formation of the product. The entire reaction mixture 
(1050 µl) was applied to a Microsorb MV 300-5 C18 (250 x 4.6 mm) analytical column (Varian) 
to measure product formation. See Appendix Figures A3, A9 and A11 for the HPLC solvents and 
gradients used for deiodination reactions of each substrate. Concentration of the dehalogenated 
product was determined from the standard curve created by addition of known amounts of product 
into the reaction mixture lacking the substrate. The ratios of the area under curve (AUC) of the 
product to AUC of IS were plotted against known concentrations of the spiked product (Appendix 
Figure A4). An equation showing the relationship between AUC and amounts of standard was 
determined by linear regression and used to calculate concentrations of dehalogenated products 
generated by the enzymatic reactions. The kinetic parameters were determined by fitting the data 
into the Michaelis-Menten equation 2-3 using Origin 6.0. The substrate 2IP had phenol as impurity 
(< 1 %). The contribution of the impurity contaminated in each substrate was subtracted from the 




2.3.1 Expression and purification of IYD homologs 
 The development of His6-tagged-SUMO fusion constructs successfully provided expression 
systems for mammalian IYDs in E. coli, which had been problematic in the past.25, 32 Consequently, 
the SUMO fusion has been used for IYD homologs from other organisms to enhance protein 
solubility. However, the IYD-SUMO fusion expression often results in later co-elution of IYD and 
the SUMO tag during SEC purification. Hence, a hhIYD construct without the SUMO tag was 
generated in an attempt to optimize its purity for crystallization (Chapter 3). Previously, IYD from 
Drosophila melanogaster was successfully expressed without the SUMO fusion,23 and hhIYD 
provided similar success. PfuIYD was initially expressed as a SUMO fusion protein by Dr. 
Abhishek V Phatarphekar, however SUMO lysis by Ulp1 was incomplete. Hence, the same non-
SUMO expression system was also implemented for pfuIYD and the protein was successfully 
expressed. The purified human IYD from the IYD-SUMO fusion and native hhIYD lacking SUMO 
were both obtained in yields of 15 – 24 mg per 1 L of culture. Soluble pfuIYD was expressed 
without a SUMO tag to a yield of about 7 mg per 1 L of culture. All three homologs were obtained 
with purity of > 98% (human IYD and hhIYD) and > 95% (pfuIYD) as evident from SDS-PAGE, 
Coomassie staining and ImageQuantTL analysis (Figure 2-3). Human IYD and hhIYD contained 
FMN at an occupancy of 95 – 105 % but only 55 – 75 % FMN occupancy of pfuIYD was observed 
among different purification batches. Several attempts were made to increase FMN occupancy of 
pfuIYD mainly to optimize protein homogeneity for crystallization trials. The efforts included 
supplementing cultures with riboflavin (10 µM) during protein expression, heat-mediated uptake 
after cell lysis,39 optimization of final buffer conditions, heat and FMN incubation with different 
temperature and time (Table 2-1). However, none of the trials above improved the FMN occupancy 
of pfuIYD. The final FMN occupancy of pfuIYD after these procedures still ranged between 59 – 
77 % which is similar to the protein yielded after purification (55 – 75 %). 
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Figure 2-3. SDS-PAGE gels of the purified IYD homologs. Lane 1 is marker with molecular 
weights of protein (kDa) indicated on the left. (A) human IYD; Lane 2 is the human IYD-SUMO 
fusion protein obtained after Ni2+ affinity chromatograpphy. Lane 3 shows human IYD and SUMO 
proteins after treated with Ulp1. Lane 4 is the purified human IYD after SEC. (B) hhIYD and (C) 
pfuIYD. 
  
Table 2-1. Conditions of buffer, temperature and time used to increase FMN occupancy of pfuIYD. 
Buffer 









50 mM sodium phosphate 300 80 0.5 77 
50 mM sodium phosphate 300 80 2 68 
50 mM Bis-tris 300 RT 12-14 75 
50 mM Bis-tris 300 80 0.5 59 
25 mM Bis-tris - RT 12-14 77 
25 mM Bis-tris 100 RT 12-14 77 
25 mM Bis-tris 200 RT 12-14 77 
PfuIYD (~150 µM) was incubated with supplemented FMN (~750 µM) and buffer at the indicated 
temperature and time prior to centrifugation (5000 × g) using an Amicon Ultra-15 centrifugal filter (10 kDa 
MW-cut off, Millipore). Then, a cycle of buffer addition and centrifugation was repeated until the filtrate 
contained no FMN as measured by UV (ε450 = 12,500 M-1 cm-1).35 The FMN occupancy represents the final 
FMN content of pfuIYD after each treatment. RT is abbreviated for room temperature. 
 
 Elution of FMN during purification of pfuIYD by SEC suggested weak affinity of FMN for the 
pfuIYD homolog and resulted in quite different FMN occupancy (50-80 %) in different protein 
fractions eluted from the SEC. Sequence analysis of pfuIYD suggested that weak affinity of FMN 
for pfuIYD may arise from a non-conserved FMN binding residue, Lys11, which appears as Arg 
in other homologs in this study (Figure 2-1). Difference in bulkiness and length of these two amino 
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acid side chains may affect FMN affinity with the protein. Hence, pfuIYD K11R mutant was 
generated to introduce the conserved Arg back to the pfuIYD sequence with the aim to increase 
FMN affinity to the protein. The pfuIYD K11R construct was generated by site-directed 
mutagenesis and expressed about 18 mg per 1 L of culture with ~95 % purity as evident from SDS-
PAGE, Coomassie staining and ImageQuantTL analysis (Appendix Figure A5). However, 
variation of FMN occupancy (60 – 75 %) of the pfuIYD K11R protein was still observed in 
different protein fractions during SEC purification. The final pfuIYD K11R protein contained 
similar FMN occupancy (up to 78%) compared to that of the wild-type (55 – 75 %).   
2.3.2 Catalytic deiodination of I2-Tyr by IYD homologs 
 Deiodination of I2-Tyr by IYD homologs was first compared by their catalytic efficiency 
(kcat/Km) to that previously reported for other IYD homologs.30, 31 Kinetic studies were performed 
using our routine radioactivity assay to measure 125I- release from radiolabeled 125I-[I2-Tyr]. Human 
IYD, hhIYD and pfuIYD (WT) exhibited kcat/Km values ranging from 0.4 – 3.4 min -1 µM-1 (Table 
2-2), which are comparable to those previously reported.30-32 Their catalytic efficiency also fell into 
the range of the kcat/Km values for other IYD homologs from eukaryotes to prokaryotes.30-32 The kcat 
values of the selected IYDs ranged between 0.44 – 7.3 min-1 while the Km values ranged between 
1 – 15 µM. Deiodination rates of I2-Tyr by pfuIYD at 25 oC was performed by Dr. Abhishek V 
Phatarphekar and displayed the lowest kcat and Km. Since pfuIYD is found in an thermophilic 
archaea, its kinetics for I2-Tyr turnover was also performed at high temperature (60 oC) to determine 
the relative deiodination rates to those measured at 25 oC. The kcat value of pfuIYD at 60 oC 
increased by ~16 fold while its Km increased by 2 fold compared to that determined at 25 oC to give 
















(min-1 µM -1) 
human IYDa 25 7.3 ± 0.2 15 ± 1 0.49 ± 0.04 
hhIYDa 25 6.7 ± 0.8 6 ± 2 1.1 ±0.4 
pfuIYD (WT)b,c 25 0.442 ± 0.008 1.0 ± 0.1 0.4 ± 0.1 
pfuIYD (WT)a,c 60 7.2 ± 0.3 2.1 ± 0.4 3.4 ± 0.7 
aDetermined from the data of Appendix Figure A6 and the kinetic parameters are comparable to that 
previously reported.30-32 Errors derive from least square fitting. bExperiment performed by Dr. Abhishek V 
Phatarphekar. cAssays performed at pH 6.8 – 6.9.  
 
2.3.3 Affinity of halotyrosine and halophenol derivatives to IYD  
 2.3.3.1 Determination of binding specificity for IYD homologs 
 Binding affinity of ligands to IYD was determined by monitoring the ability of each ligand to 
quench the fluorescence of FMNox in an active site of IYD. To determine binding specificity of 
human IYD, hhIYD and pfuIYD (WT), binding assays of I-Tyr and 2IP for each IYD homolog 
were performed. The Kd values of I-Tyr to all IYDs ranged from 0.03 – 8.2 µM (Figure 2-4). The 
Kd values of I-Tyr for human IYD and pfuIYD fell into a sub-µM range, which is similar to that 
previously observed in mouse IYD.25 Interestingly, the affinity of pfuIYD for I-Tyr at 60 oC 
maintained the same as that observed at 25 oC (Table 2-3, Appendix Figure A7). On the other hand, 
the affinity of hhIYD for I-Tyr is ~90- and 200-fold less than that of human IYD and pfuIYD, 
respectively. Lower stringency of hhIYD affinity for I-Tyr implied that the enzyme may share its 
























I-Tyr 8.4a, 8.3b  0.09 ± 0.02g   6.9 ± 0.4 7.3 ± 0.8 1.0 ± 0.2 
2IPg 8.4a, 8.5b 1,410 ± 70  0.26 ± 0.01 4,100 ± 400 (6.3 ± 0.7)×10
-5  
pfuIYDh I-Tyr (25o C) 8.4a, 8.3b 0.04 ± 0.02 - - - 
 I-Tyr (60oC)    0.03 ± 0.02 - - - 
 2IP (25 o C) 
8.4a, 8.5b 
     79 ± 4 - - - 
 2IP (60 o C)    270 ± 20 1.0 ± 0.2 4,000 ±2,000 (3 ± 1)×10
-4 
hhIYD I-Tyr 8.4a, 8.3b 8.2 ± 0.5       16 ± 1      12 ± 2 1.3 ± 0.3 
 2IP 8.4a, 8.5b      67 ± 2 0.17 ± 0.02 4,100 ± 800 (4 ± 1)×10-5 
 2BP 8.5b    260 ± 20 <0.002e - - 
 2IPCOOH 8.6a   24.1 ± 0.7 0.186 ± 0.006 7,100 ± 600 (2.6 ± 0.2)×10-5 
 4A2IP 9.3a      96 ± 3 - - (2.6 ± 0.2)×10-4 
 2IPCN 6.7a 1.44 ± 0.05 < 0.001f - - 
apKa values of the phenolic protons were calculated with the ACE and JChem acidity and basicity calculator 
(https://epoch.uky.edu/ace/public/pKa.jsp). bpKavalues were also determined experimentally as published 
previously.40-42 cKd values were determined from Figure 2-4 to 2-6 and Figure A7. dKinetic parameters were 
determined from Appendix Figures A8. ekcat value was estimated from Figure A11. fkcat value was estimated 
from Figure A9. Errors derive from least squares fitting. gExperiments performed by Zuodong Sun. hAssays 
performed at pH 6.9.  
 
 
Figure 2-4. Quenching of FMNox fluorescence upon ligand binding to IYD at 25 oC. Human IYD 
(4.3 µM, 200 mM KCl), hhIYD (2.5 µM) in 100 mM potassium phosphate, pH 7.4 and pfuIYD 
(2.5 µM) in 100 mM potassium phosphate, pH 6.9 were stirred at 25 oC for 30 min prior to addition 
of the indicated ligand. The Kd values derived from the best fit of the data (solid lines) to equation 
2-4. Complete fluorescence quenching by 2IP was limited by its solubility. 
 
 The three IYD homologs exhibited different affinities for 2IP with Kd values ranging from 67 – 
1,410 µM (Table 2-3, Figure 2-4). hhIYD and pfuIYD showed similar affinities with 2IP (Kd = 65 
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– 80 µM) while human IYD expressed the weakest affinity with a Kd almost 20-fold more than that 
of pfuIYD and hhIYD. Binding of pfuIYD with 2IP was also performed at 60 oC. In contrast to I-
Tyr, a decrease in the affinity for 2IP was observed with the Kd of ~3.5 fold more than that 
determined at 25 oC (Table 2-3, Appendix Figure A7).  
 The binding studies of I-Tyr and 2IP showed that human IYD exhibited almost 16,000-fold 
increase in the Kd for 2IP versus I-Tyr while hhIYD exhibited the smallest difference (~8 fold). 
PfuIYD expressed the greatest binding promiscuity as it clearly binds I-Tyr as tightly as human 
IYD but still binds 2IP with similar affinity as hhIYD. Different binding selectivity among the three 
IYD homologs suggested that IYD from bacteria and archaea may express substrate promiscuity 
for different purposes of dehalogenation while human IYD maintains high substrate specificity 
toward I-Tyr to maintain iodide homeostasis.  
 2.3.3.2 The contribution of the zwitterion on binding different halotyrosines to hhIYD 
 The results from binding specificity suggested that affinity of hhIYD has the least dependence 
on the zwitterion of all selected IYD homologs. Small differences in binding strength between I-
Tyr and 2IP for hhIYD (~8-fold difference in the Kd values) stimulated further analysis of its 
affinity for a series of 3-halotyrosines (X-Tyr) and 2-halophenols (2XP) to assess the contribution 
of the zwitterion on binding of different halo-substituents 
 Previously, affinities of X-Tyr for mouse IYD and human IYD were determined with Kd values 
of I-Tyr, Br-Tyr and Cl-Tyr were all in the sub-µM while that of F-Tyr bound with a Kd about 10-
fold higher (Table 2-4). A similar trend was observed for hhIYD, but its Kd value for each X-Tyr 
is one order of magnitude higher than those of the mammalian IYDs (Table 2-4). Weaker binding 
of X-Tyr to hhIYD also suggested that the zwitterion of X-Tyr had less effect on binding to hhIYD 
compared to mammalian IYDs. However, the zwitterion was still essential to maintain binding of 
different halotyrosines since their Kd values range within less than an order of magnitude (Table 2-
4, Figure 2-5). The difference in affinity of X-Tyr may in part be affected by different abilities of 
the halo-substituents to shift acidity of the phenol (Table 2-4). Previous studies with human IYD 
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demonstrated the preferential binding of human IYD to the phenolate form of I2-Tyr.32 Hence, 
changes in the pKa caused by different halo-substituents can potentially affect affinity of X-Tyr and 
hhIYD as the proportion of the phenolate changes. Most affinity of X-Tyr to hhIYD followed this 
trendency except for Cl-Tyr. Its affinity may be more influenced by the size of a chloro-substituent. 
Otherwise, increased affinity to hhIYD was observed when the phenolic proton is more acidic 
(Table 2-4). However, the results are not very obvious due to fairly small differences among the 
pKa (8.48 - 8.86) and the Kd values of X-Tyr (Table 2-4). 
Table 2-4. Binding affinity of halotyrosines (X-Tyr) and halophenols (2XP) for IYD 
Halogen 
(X) 




mouse IYDb human IYDb hhIYDc human IYDd hhIYDc 
I 8.53 0.09 ± 0.04 0.09 ± 0.02   8.2 ± 0.5 1,410 ± 70   67 ± 2 
Br 8.48 0.15 ±0.02 0.10 ± 0.01   2.1 ± 0.3 -   260 ± 20 
Cl 8.35 0.11 ± 0.03 0.14 ± 0.02   6.2 ± 0.3 -   410 ± 30 
F 8.86  1.3 ± 0.20   1.3 ± 0.40 51 ± 2 - 22,700 ± 900 
aValues determined previously.41 bDetermined previously.32, 43 cDetermined from the data of Figure 











Figure 2-5. Quenching of FMNox fluorescence upon ligand binding to hhIYD. hhIYD (2.5 µM) in 
100 mM potassium phosphate, pH 7.4 was stirred at 25 oC for 30 min prior to addition of the 
indicated ligand. The Kd values derived from the best fit of the data (solid lines) to equation 2-4. 
Complete fluorescence quenching by 2XP was limited by their solubility. 
 In contrast to X-Tyr, contribution of the halogens to the binding affinity is more pronounced for 
halophenols as their binding strength for hhIYD dramatically dropped from 2-iodophenol to 2-
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fluorophenol (Table 2-4, Figure 2-5). This change is evident by their widely distributed Kd values 
from 67 µM to 23 mM. The results suggested that the zwitterion is more significant on binding to 
hhIYD when the halogens are smaller in size.    
 2.3.3.3 Determination of binding affinity of iodophenol derivatives to hhIYD 
 The binding studies of different halotyrosines for hhIYD showed that hhIYD has the greatest 
promiscuity for the iodo-substituted derivatives (I-Tyr and 2IP). Hence studies of hhIYD binding 
promiscuity were extended to three additional iodophenol derivatives, including ones with an 
electron donating group (4-amino-2-iodophenol, 4A2IP), an electron withdrawing group (4-
hydroxy-3-iodobenzonitrile, 2IPCN) and an extra charge (4-hydroxy-3-iodobenzoate, 2IPCOOH). 
Previously, the phenolate rather than phenol form showed preferential binding to human IYD. The 
derivatives with the amino and cyano groups were used to shift the acidity of the phenolic proton 
(Table 2-3). The estimated pKa for 4A2IP is slightly higher than that of 2IP (~0.3 pKa unit). As 
speculated, its affinity for hhIYD is slightly weaker than 2IP (~1.45 fold) (Table 2-3, Figure 2-6) 
as its phenolic proton is less acidic than that of 2IP. 2IPCN exhibited a more substantial difference 
in a Kd value compared to 2IP (~46 fold) because of a greater difference in pKa (2 pKa units) (Table 
2-3, Figure 2-6). The affinity of 2IPCN was even stronger than I-Tyr, which implied that the 
zwitterion may not be necessary for substrate recognition and turnover for hhIYD. The Kd of 
2IPCOOH is intermediate between 2IPCN and 2IP and the negative charge of the carboxylate anion 







Figure 2-6. Quenching of FMNox fluorescence upon ligand binding to hhIYD. hhIYD (2.5 µM) in 
100 mM potassium phosphate, pH 7.4 was stirred at 25 oC for 30 min prior to addition of the 
indicated ligand. The Kd values derived from the best fit of the data (solid lines) to equation 2-4.  
2.3.4 Catalytic deiodination of I-Tyr and mono-halophenols  
 Enzyme turnover of each mono-halogenated compound was determined by measuring 
formation of its deiodinated product after separation by reverse-phase HPLC (Appendix Figure A3, 
A9 and A11). The initial rates as a function of substrate concentrations were used to determine the 
kinetic parameters (Appendix Figure A8). A kcat/Km of deiodination of I-Tyr by human IYD is 2-
fold more than that recently determined for Drosophila IYD.23 Their kcat values are almost identical 
and the Km for human IYD is only ~1.5 fold-less than that of Drosophila IYD. The catalytic 
efficiency of I-Tyr turnover by human IYD is only 2-fold higher than that of I2-Tyr (Table 2-2 and 
2-3). Their kcat values are experimentally indistinguishable and the Km of I-Tyr is only ~2-fold lower 
than that of I2-Tyr. Lacking the zwitterion greatly decreased efficiency of deiodination of 2IP by 
human IYD with a kcat/Km five orders of magnitude lower than that of I-Tyr (Table 2-3). Its kcat is 
lower by 20-fold and the Km is higher by 560 fold compared to that of I-Tyr.  
 HhIYD exhibited almost identical catalytic efficiency (kcat/Km) for deiodination of I-Tyr as 
human IYD, despite about 90-fold weaker affinity with I-Tyr (Table 2-3). Again, loss of catalytic 
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efficiency was also observed for deiodination of 2IP although its affinity is about 20-fold greater 
than human IYD. The kcat of 2IP turnover by hhIYD is even lower than that of human IYD (~45%) 
while their kcat/Km values are still in the same order of magnitude. The binding and kinetic results 
of human IYD and hhIYD with I-Tyr and 2IP exhibited no correlation between affinity and 
catalysis. A kcat of 2IP turnover by pfuIYD at 60 oC is ~4- and ~6-fold higher than that of human 
IYD and hhIYD at 25 oC. An increase in the kcat of pfuIYD is expected for rates at higher 
temperature. However, its Km is almost identical to that of human IYD and hhIYD, resulting in one 
order of magnitude higher kcat/Km. All IYD homologs expressed low deiodination rates of 2IP. 
However, their slow rates were confirmed to derive from enzymatic activity by performing 
deiodination of 2IP in the presence of free FMN instead of IYD. The reaction containing FMN (2.5 
µM), 2IP (5 mM) and dithionite (0.5%) was performed under a standard condition. If phenol was 
generated, the amount was below the detection threshold of 3 nmol after 2 h (Appendix Figure 
A10). Turnover of 2-bromophenol (2BP) was further investigated but very slow debromination 
rates were observed with the detected phenol less than threshold of 3 nmol after 4 h. (Appendix 
Figure A11).  
 Catalytic activity of hhIYD with three iodophenol derivatives was further determined to study 
whether active site affinity or a charge group of a substrate will have an influence on catalysis. 
2IPCOOH has slightly tighter affinity with hhIYD than 2IP. However, its kcat/Km is still within an 
order of magnitude with that of 2IP. The results implied the rate of catalysis does not correlate with 
substrate affinity. More obvious results were shown by the last two examples where a kcat/Km of 
4A2IP turnover is ~6-fold increased from that of 2IP which contrasts to its weaker affinity to 
hhIYD. Surprisingly, no 4-cyanophenol product was detected over the detection threshold from the 
deiodination of 2IPCN by hhIYD (Appendix Figure A9) although the ligand binds hhIYD even 
more tightly than I-Tyr. The binding and catalysis studies suggested that tight active site binding 





 The binding of human IYD, hhIYD and pfuIYD to I-Tyr and 2IP suggested different binding 
specificity between IYDs from eukaryotes and prokaryotes. Despite their binding differences, all 
three IYDs have similar catalytic specificity as their kcat/Km values for iodotyrosines distributed 
within an order of magnitude and are 4 – 5 orders of magnitude higher than those of 2IP. Clearly, 
human IYD controls both binding and catalytic selectivity to iodotyrosines for efficient 
maintenance of iodide for a thyroid function. The bacterial IYD and archaeal IYD share more 
promiscuity for binding 2IP but low deiodination rates of 2IP suggested that 2IP is not their primary 
substrate. Both prokaryotic IYDs still reserve their deiodinase activity for iodotyrosines which may 
be physiologically relevant. However, their function is still unknown. The higher kcat of I2-Tyr 
turnover by pfuIYD at 60 oC versus 25 oC is expected for IYD from thermophilic P. furriosus 
thriving at an optimal temperature of 100 oC.44 Interestingly, its Kd for I-Tyr and Km for I2-Tyr at 
25 oC and 60 oC are maintained but the Kd for 2IP at 60 oC is increased from that of 25 oC by ~3.5 
fold. These observations suggested that at high temperature, the enzymatic machinery of pfuIYD 
is designated for recognition and catalysis of halotyrosines over 2IP. It is still a mystery but very 
tempting to believe that the truncated loop of pfuIYD may in part mediate binding and catalysis of 
halotyrosines at high temperature. Investigations on substrate specificities of the selected IYDs 
suggest that an increase in binding stringency was evolved from the archaeal IYD to human IYD 
but the catalytic selectivity for halotyrosines was already fine-tuned and exists in the primitive 
organism like archaea. 
 Further investigations on active site binding for hhIYD revealed that substrate affinity can be 
altered by two features. Initially, only an ~8 fold-difference in the Kd of I-Tyr and 2IP for hhIYD 
implied that the zwitterion may not contribute much to its affinity. However, the drastic decrease 
in affinity of hhIYD with a series of phenols with different halo-substituents demonstrated that the 
zwitterion is still essential for ligand affinity to hhIYD especially when the halo-substituents 
become smaller. The necessity of the zwitterion was also illustrated by crystallographic studies of 
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mouse and human IYD showing bridging interactions from the zwittion of iodotyrosines to three 
active site lid residues and the isoalloxazine ring of FMN.32, 43 Mutations of each individual active 
site residue or modifications of the carboxylate or amino group of I-Tyr to remove charges also 
exhibited decreases in substrate binding affinity.23, 25, 45 However, binding studies of iodophenol 
derivatives for hhIYD revealed that the zwitterion is not the only key feature for active site binding 
as changes in acidity of the phenolic pKa introduced by different para-substituents is also important 
for ligand affinity. 2IPCN binds more tightly than 2IP and even more than I-Tyr potentially because 
its phenolic proton is significantly more acidic than that of 2IP and I-Tyr (Table 2-3), leading to a 
greater proportion of the phenolate anion to provide an electrostatic interaction to the backbone 
Ala64 (equivalent to Ala126 in mouse IYD as described in Chapter 1). The importance of the 
acidity of the phenolic proton was evident in the weak affinity of a methyl-tyrosine to mouse IYD 
(Kd > 1.5 mM) due to high pKa (pKa = 10.4)45 of its phenolic proton.22, 32 
 However, high affinity of the active site does not ensure an increase in deiodination rates by 
IYD. This behavior is evident by the failure to improve catalytic efficiency of I-Tyr for human IYD 
and pfuIYD, which exhibited stronger affinity for I-Tyr than hhIYD. Also, high affinity of 2IP to 
hhIYD and pfuIYD compared to human IYD does not increase their kcat/Km for 2IP turnover. 
Substrate affinity and steady-state kinetics of 2-iodophenol derivatives for hhIYD demonstrated 
that 2IPCOOH binds hhIYD almost 3-fold more tightly than 2IP but showed slightly lower kcat/Km 
(~1.6 fold). On the contrary, 4A2IP showed weaker affinity by hhIYD versus 2IP but exhibited a 
larger kcat/Km by ~6 fold. The most striking evidence demonstrating no correlation between binding 
and catalysis is that affinity for 2IPCN by hhIYD is even stronger than I-Tyr but no detectable 
turnover was observed. These results clearly confirmed that tight binding is not the only 
determinant for IYD catalysis. This observation implied IYD has additional requirements upon 
substrate coordination to trigger FMN chemistry for its reductive deiodination. Since lack of the 
zwitterion is the only difference 2IP has compared to I-Tyr, the absence of the zwitterion in 2IP is 




 The kcat/Km values of I2-Tyr turnover for human IYD, hhIYD and pfuIYD fell within the range 
reported for other IYD homologs from different eukaryotes and prokaryotes. Their catalytic 
efficiency for I-Tyr is also within an order of magnitude from that of I2-Tyr despite being 
determined from different assays. Binding studies of 2IP compared to I-Tyr for all three IYDs 
displayed different substrate recognition between the selected eukaryotic and prokaryotic IYDs. As 
expected, human IYD exhibited the highest binding specificity for I-Tyr with an almost 16,000 fold 
difference in the Kd of I-Tyr and 2IP. PfuIYD and hhIYD shared more binding promiscuity with 
2IP. Their Kd values for I-Tyr and 2IP (~2,000 fold and ~8 fold, respectively) are much less than 
the 16,000 fold. The increase in affinity of both prokaryotic IYDs for 2IP was thought to potentially 
increase their catalytic efficiency for 2IP. However, their kcat/Km values for 2IP turnover are still 
low and within an order of magnitude to that of human IYD. Hence, all selected IYDs displayed 
the same catalysis preference for I-Tyr with kcat/Km of 4 – 5 orders of magnitude higher than that 
of 2IP. Low deiodination rates of 2IP suggested that it is not the primary substrate for IYDs 
including those from bacterium and archaea. Different binding specificity but similar catalytic 
selectivity also suggested that IYD has different criteria for binding and turnover. Tight substrate 
binding does not ensure IYD catalysis as apparently evident by no detectable 2IPCN turnover 
despite its strongest affinity to hhIYD. The phenolate anion is key for affinity of iodophenol 









Chapter 3: Structural and functional analysis for the slow turnover of 2-iodophenol by 
hhIYD 
3.1 Introduction 
 Flavoproteins catalyze a very broad spectrum of redox processes by different mechanisms based 
in part by its ability to participate in both one- and two-electron processes.46-49 The oxidized FMN 
(FMNox) can be reduced via either a single two-electron process to generate a fully reduced-state 
hydroquinone (FMNhq) or by two single electron steps to first form its one-electron reduced 









Figure 3-1. Interconversion of the three oxidation states of FMN. 
 
 Enzymes within the nitro-FMN reductase superfamily can be distinguished by their ability to 
promote one and two electron chemistry. For example, reduction of nitroaromatic compounds is 
catalyzed by nitroreductases via a two electron pathway51-53 and reductive dehalogenation of 
halotyrosines is catalyzed by IYD via a one-electron pathway.22, 32 These two processes are often 
distinguished by the patterns of hydrogen bonding to N5-FMN. The crystal structures of 
nitroreductases show hydrogen bonding between the amide backbone and N5-FMN, which may in 
part be related to stabilizing the two-electron process.51, 53 Alternatively, hydrogen bonding to N5-
FMN in IYD is established from the side chain hydroxyl group of Thr and this hydrogen bonding 
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pattern is often associated with activation of the one-electron pathways which consequently 
promotes FMNsq formation.24, 32 
 The crystal structures of human IYDI-Tyr demonstrated that hydrogen bonding to N5-FMN is 
established upon coordination of halotyrosine substrates.32 Binding of I-Tyr to the active site of 
human IYD allows the Thr235 side chain to approach N5-FMN within hydrogen bonding distance 
(Figure 3-2). Further studies on the redox properties of FMN in human IYD revealed that 
association of the substrate analog fluorotyrosine (F-Tyr) to human IYD can switch the redox 
chemistry of FMN from two- to one-electron processes.32 This change is evident by accumulation 
of FMNsq during the reduction of FMN in human IYD in the presence of F-Tyr. However, this same 
stabilization is not detected when F-Tyr is absent.32 The crystallographic and redox studies 
suggested that IYD requires coordination of the substrate to initiate one-electron chemistry for its 
deiodination take place. 
 
Figure 3-2. Conformational change upon association of I-Tyr with human IYD. Superimposition 
of human IYD in the absence (gray) and presence of I-Tyr (orange). 
 
 It is explained in this Chapter why catalytic turnover of 2IP is still very low (kcat/Km = (4 ± 1)×10-
5 min-1 µM-1) despite its high affinity for hhIYD (Kd = 67 ± 2 µM). Crystallographic studies and 
redox titration of hhIYD in the alternative presence of 2IP and I-Tyr were also used for hhIYD to 
contrast the ability of these two substrates to template the active site of hhIYD for its catalysis.  
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3.2 Experimental Procedures 
3.2.1 Materials 
 Sparse matrix screens including Index HR2-144 (Hampton Research), Cryos Suite (QIAGEN) 
and PEGs II (QIAGEN) were used for crystal screening. All other reagents used for crystallization 
were purchased from Hampton Research. Xanthine and xanthine oxidase were obtained from 
Sigma-Aldrich. Other materials are described in Chapter 2 (2.2.1). 
3.2.2 Expression and purification of hhIYD 
 Expression, purification and concentration determination of hhIYD are described in Chapter 2 
(2.2.2 and 2.2.5) Enzyme concentration used for each experiment was determined based on FMN 
concentration to represent the native active site. 
3.2.3 Crystallization 
 Crystallization conditions were determined using sparse matrix screening with commercially 
available screens and a Phoenix crystallization robot. Crystals of hhIYD without ligand were grown 
by mixing 1 µl of protein  (14 mg/ml, in 50 mM sodium phosphate pH 7.4, 100 mM NaCl, 0.5 mM 
TCEP and 10 % glycerol) in 0.8 µl of well solution containing 80 mM Tris-HCl pH 8.5, 100 mM 
MgCl2, 24% (w/v) PEG 4000 and 20% glycerol. To obtain a co-crystal of hhIYD and I-Tyr, hhIYD 
(14 mg/ml (final) in 25 mM HEPES pH 7.4, 0.5 mM TCEP and 10 % glycerol) was incubated with 
2 mM (final) of I-Tyr overnight at 4 oC. Crystals were grown by mixing 0.8 µl of the hhIYDI-Tyr 
mixture in 1 µl of a well solution containing 100 mM HEPES pH 7.5, 150 mM MgCl2, 25% (w/v) 
PEG 3350, 2 mM I-Tyr and 15% glycerol. To obtain a co-crystal of hhIYD with 2IP, hhIYD (16 
mg/ml (final) in 25 mM HEPES pH 7.4, 0.5 mM TCEP and 10 % glycerol) was incubated with 2 
mM (final) of 2IP overnight at 4 oC. Crystals were grown by mixing 1 µl of hhIYD2IP mixture in 
0.8 µl of a well solution containing 100 mM Tris-HCl pH 9, 200 mM MgCl2, 2 mM 2IP, 17% (w/v) 
PEG 8000, 17% glycerol and 10% (v/v) ethylene glycol. All crystals were grown at 20 oC using 
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hanging drop vapor diffusion. The crystals appeared within 3 days. Each crystal was then flash 
frozen in liquid nitrogen directly from the drop. 
3.2.4 Data Collection and Structure Determination 
 Diffraction data were collected at the 12-1 and 7-1 beamlines at the Stanford Synchrotron 
Radiation Lightsource (SSRL). The diffraction data were processed using either XDS/Aimless54 
(for PDB: 5KO7 and 5KO8) or HKL2000/Scalepack55 (for PDB: 5KRD). Phases were determined 
by molecular replacement using PHASER56 and the mouse IYD (PDB: 3GB5) was used as the 
search model.24 All three structures were built and refined by iterative rounds of model-building in 
COOT57 and refinement in PHENIX.58 All structural figures were drawn in PyMOL (Schrödinger, 
LLC). X-ray diffraction and data processing were performed by Dr. Jennifer Kavran. 
3.2.5 Anaerobic Redox Titration.  
 Anaerobic titration of hhIYD was performed using a xanthine/xanthine oxidase system as 
previously described.32, 59, 60 Solutions of hhIYD (20 μM), potassium phosphate (100 mM, pH 7.4), 
NaCl (500 mM), glycerol (10% v/v), xanthine (1 mM) and methyl viologen (13 µM) were purged 
by bubbling with Ar for 30 min to remove molecular oxygen. Reduction was initiated by addition 
of xanthine oxidase (140 µg/ml). Reduction of hhIYD was repeated in the alternative presence of 
F-Tyr (500 µM) and 2IP (800 µM) to study the effect of ligand on the redox properties of hhIYD.  
 
3.3 Results 
3.3.1 Structural studies of hhIYD 
 Crystal structures of hhIYD in the absence and alternative presence of I-Tyr and 2IP were 
established for structural comparison to study a correlation between active site binding and turnover 
of 2IP. All the structures were determined by X-ray diffraction and molecular replacement using 
mouse IYD as a model (PDB: 3GB5).24 The crystals of hhIYD, hhIYDI-Tyr and hhIYD2IP 
diffracted X-ray with the resolution of 2.3 Å, 2.2 Å and 2.1 Å, respectively. Data collection and 
refinement statistics are summarized in Table 3-1. All three hhIYD structures have two polypeptide 
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chains per asymmetric unit but only the structure of hhIYD without a ligand existed in a biological 
dimer with two identical chains. The biological dimer forms of hhIYDI-Tyr and hhIYD2IP were 

















































Table 3-1. Data collection and refinement statistics  
 
Protein   hhIYD   hhIYDI-Tyr  hhIYD2IP 
Ligands   FMN   FMN and I-Tyr  FMN and 2IP 
Protein Data Bank code 5KO7   5KO8   5KRD 
Data collection 
   Space group  P 21 21 2   P 62 2 2   P 64 2 2 
   Unit cell parameters 
 a, b, c (Å) 92.18, 110.88, 43.29 152.72, 152.72, 87.20 154.70, 154.70, 88.88 
 α, β, γ (o) 90, 90, 90  90, 90, 120  90, 90, 120 
   Resolution (Å)a  36.96–2.25 (2.32–2.25) 38.18–2.15 (2.22–2.15) 20.00–2.10 (2.17–2.10)   
   Wavelength (Å) 1.127   0.980   0.980 
   No. of unique  21,635 (1,685)  33,077 (2,795)  36,523 (3,607) 
       reflectionsa 
No. of observed  149,492    647,766   267,636 
         reflections 
   Completeness (%)a 98.9 (88.4)  99.9 (100)  98.8 (99.5) 
   Redundancya  6.9 (5.1)   19.6 (20.4)  7.3 (7.2) 
   Rsym (%)a,b  7.5 (145)  14.7 (375)  10.7 (100) 
   Rp.i.m (%)a,c  3.1 (69.4)  3.4 (84.0)  5.7 (100) 
   I/σIa   15.2 (1.1)  16.8 (1.1)  15.2 (1.0)  
Refinement 
   Resolution used in 35.4–2.3   38.2–2.2   20.0-2.1 
refinement (Å) 
   Rwork (%)/Rfree (%)d   21.6/25.4  19.1/23.2  17.7/22.1 
   No. of atoms 
      Protein  6,336   6,925   6,401    
      Heteroatoms  100 (FMN)  174 (FMN and I-Tyr) 116 (FMN and 2IP)  
      Solvent  62   128   126 
   Mean B-factor (Å2) 
      Protein  71.25   62.44   60.16 
 Waters  53.47   50.96   56.18 
      FMN  56.22   44.21   45.74 
      I-Tyr  –   62.57   – 
      2IP   –   –   65.46 
   RMSD from ideality 
      Bond lengths (Å) 0.003   0.005   0.014    
      Bond angles (o) 0.707   0.842   1.386 
   Ramachandran analysis 
      Favored (%)  99.49   98.60   99.49 
      Allowed (%)  0.51   1.40   0.51 
      Outliers  0   0   0 
a   The values in parentheses are for the highest resolution shell.  
b   Rsym =ΣhklΣi |Ii - <I>| /ΣhklΣi Ii , where Ii is the intensity of an individual reflection and <I> is the 
mean intensity obtained from multiple observations of symmetry related reflections. 
c   Rp.i.m =Σhkl√((1/(n-1)) Σi |Ii - <I>| / ΣhklΣi Ii, where Ii is the intensity of an individual reflection and <I> 
is the mean intensity obtained from multiple observations of symmetry related reflections. 
d  Rwork = Σhkl (|Fobs| - | Fcalc | ) / Σhkl | Fobs |  where Fobs is an observed amplitude and Fcalc a calculated 





3.3.1.1 Structure of hhIYD 
 The structure of hhIYD in the absence of ligand is consistent with the mammalian IYDs that 
have common features of the nitro-FMN reductase superfamily, to which IYD belongs to.24, 32 The 
biologically relevant form of hhIYD is an α2 dimer with - fold and domain swaps at each N and 
C terminus. The FMN cofactor is non-covalently bound in active sites formed by the dimer 
interface (Figure 3-3A). The hhIYD structure is superimposable on both mouse and human 
counterparts (mouse IYD: RMSD of 0.85 Å for 304 Cα atom comparison of PDB: 5KO7 versus 
3GB5; human IYD: RMSD of 0.77 Å for 321 Cα atom comparison of PDB: 5KO7 versus 4TTB) 
(Appendix Figures B1-A and B1-B). Similar to both mammalian IYDs, an active site lid of hhIYD 
(residues 95 – 112) is unstructured as indicated by the lack of electron density for the active site lid 
region (Figure 3-3 A). However, the loop of hhIYD (residue 133 – 145) is present despite the 
absence of I-Tyr. The equivalent loop in human IYD is detected only when I-Tyr is bound while 
the entire loop of mouse IYD was barely built even in the presence of I-Tyr (Appendix Figure B2). 
The presence of the loop of hhIYD is rationalized by substitution of Ala in mammalian IYDs with 
Pro13761, 62 in hhIYD that can introduce rigidity into the region. In addition, Asp138 and Thr140 of 
hhIYD (substituted with Gln and Lys in mammalian IYDs) are within hydrogen bonding distance, 







Figure 3-3. Structures of hhIYD and the active site environment. (A) hhIYD (gray) (B) hhIYDI-
Tyr (cyan) and hhIYD2IP (green). The associated FMNox co-factor is present in yellow (carbon 
atom). Black dashed lines represent hydrogen bonding within 2.5 – 2.9 Å and gray dashed lines 
indicate a distance of 4 Å. The unstructured active site lids in (A) hhIYD and (C) hhIYD2IP 
generate two discontinuous ends as indicated by (*). 
 
3.3.1.2 Structure of hhIYDI-Tyr 
 The structure of hhIYDI-Tyr is nearly superimposable with the structure of hhIYD in the 
absence of I-Tyr (RMSD of 0.23 Å for 345 Cα comparison of PDB: 5KO8 versus 5KO7) (Appendix 
Figure B1-C) except for the detectable active site lid (residues 95 - 112) (Figure 3-3 B). The lid 
was also observed in the co-crystal complexes of mouse and human IYDs with I-Tyr. Coordination 
of I-Tyr stabilizes the lid by using its zwitterion to establish interactions with the side chains of 
three active site lid residues, Glu91, Tyr95 and Lys116 (Figure 3-3 B). The zwitterion also offers 
hydrogen bonding through its ammonium to the O4-FMN and its carboxylate to the N3-FMN. 
Besides, electrostatic interactions from the zwitterion of I-Tyr, the hhIYDI-Tyr complex is likely 
to be stabilized by -stacking between an aromatic ring of I-Tyr and FMN, hydrogen bonding of 
the phenolate of I-Tyr to an amide backbone of Ala64 and 2’OH-ribityl of FMN. All these 
interactions are also present in both mammalian crystal complexes with I-Tyr.  
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 The entire lid of hhIYDI-Tyr could be built for one chain but not for the other due to 
insufficient electron density for residues 98-100. This behavior implied that the lid is somewhat 
dynamic even when I-Tyr is bound. In addition, I-Tyr in the active site of hhIYD is present in two 
conformations as evident by an unbiased difference map of I-Tyr and an anomalous signal from 
the iodo atom (Figure 3-4 A). In more prevalent conformation, the aromatic ring stacks over FMN 
with the C-I bond aligning over a C4a-N5 bond of FMN (4.0 Å from an iodo atom to N5-FMN) 
(Figure 3-3 B and Figure 3-4 A), which is similar to the single conformation observed with the 
mouse and human IYD. The second conformation contains I-Tyr with its aromatic ring flipped by 
~180o with the C-I bond pointing toward Phe110. The presence of this alternative conformation is 
likely explained by the π-interaction given by Phe110 to the C–I bond.63 An equivalent Phe is not 







Figure 3-4. Substrates and FMNox complex in the active site of hhIYD (A) Two configurations of 
I-Tyr (B) Single configuration of 2IP. FMNox is presented in yellow (carbon atoms). The unbiased 
difference map (Fo-Fc) countoured at +3σ are indicated in green mesh. The anomalous difference 
maps contoured at +3σ are shown in orange mesh. 
 
 3.3.1.3 Structure of hhIYD2IP 
 The co-crystal structure of hhIYD with 2IP is nearly superimposable with the structure of hhIYD 
in the absence of ligand with RMSD of 0.30 Å for 337 Cα atom comparison of PDB: 5KRD versus 
5KO7 (Figure B1 D). Unlike I-Tyr, 2IP lacks the zwitterion to establish interactions with the lid 
residues and FMN, hence no detectable active site lid was observed (Figure 3-3 C). The unbiased 
difference map and the anomalous difference map showed the electron density for a hydroxyl group 
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and one position of an iodo atom indicating that 2IP is located with a single orientation. 
Undetectable electron density for an aromatic ring of 2IP suggested that 2IP is dynamic in the active 
site of hhIYD (Figure 3-4 B). However, 2IP resides in the active site with a similar orientation to 
I-Tyr in the mammalian IYDs having its aromatic ring above FMN and its C–I bond aligns over 
C4a-N5 bond of FMN (4 Å). A distance from the iodo atom of 2IP to N5-FMN is also similar to 
that observed in hhIYDI-Tyr (4.0 Å) (Figure 3-1 B-C). The complex of hhIYD2IP is likely 
stabilized by -stacking between the aromatic rings of 2IP and FMN together with a hydrogen 
bonding from the phenolate to Ala64 backbone and 2’OH-ribityl of FMN.  
3.3.2 Reduction of FMN in the active site of hhIYD 
 Previous studies demonstrated that deiodination by IYD is driven by an one-electron process.22, 
32, 52 This is evident by detection of the one-electron reduced FMNsq during the reduction of 
mammalian IYDs in the presence of either I-Tyr or an inert substrate analog fluorotyrosine (F-Tyr). 
To investigate slow deiodination of 2IP by hhIYD, similar redox titration studies were repeated 
with hhIYD in the presence of 2IP to learn how its active site coordination affects FMN chemistry 
compare to F-Tyr.  
 Reduction of hhIYD was performed using xanthine/xanthine oxidase.59, 60 In the absence of 
ligand, FMNox bound to hhIYD (λmax = 446 nm and shoulder near 470 nm) was reduced without 
detection of the FMNsq (λmax = 590 nm) (Appendix Figure B3) suggesting a preferential two-
electron process. Then, reduction of hhIYD was performed in the presence of an inert substrate 
analog F-Tyr. Binding studies confirmed that this analog binds hhIYD (Kd = 46 ± 2 µM) (Figure 
B4) but is not subject to dehalogenation.22, 32 About 10-fold excess of Kd was used for the redox 
titration. FMNsq was detected during reduction of hhIYD with F-Tyr present, indicating a switch 
























Figure 3-5. UV spectrum monitoring reduction of FMN bound to hhIYD in the presence of ligands 
(A) F-Tyr and (B) 2IP. FMNox (446 nm) decreases upon reduction and accumulated FMNsq (590 
nm) is detected in (A) but not in (B).  
 
 2IP was used to assess its ability to stabilize FMNsq as it is not practical to use the analog  2FP 
due to its very weak affinity for hhIYD (Kd = 20 ± 1 mM) (Appendix Figure B4). 2IP was used 
instead due to its slow deiodination by hhIYD with the turnover number less than one during the 
time needed for its redox titration experiment (40 min). Unlike F-Tyr, accumulation of FMNsq was 
not observed during the reduction of hhIYD when 2IP is present (Figure 3-5 B). This finding 
suggested 2IP lacks the ability to shift the chemistry of FMN from a two- to one-electron process.  
3.4 Discussion 
 Success in co-crystallization of hhIYD2IP and the redox titration studies provided an 
explanation for the slow deiodination of 2IP by hhIYD. Crystallographic studies demonstrated that 
2IP resides in the active site of hhIYD but is mobile. It does mimic the orientation of I-Tyr. Unlike 
I-Tyr, 2IP lacks ability to order the active site lid. Both I-Tyr and 2IP stack over FMN and their C–
I bonds are aligned over a reactive center C4a–N5 bond of FMN. In several flavoproteins, π-
stacking either from the protein or substrate to an isoalloxazine ring of FMN is essential to fine-
tune flavin redox chemistry.64, 65 In addition, close proximity of substrates to a highly-reactive 
region, C4a-N5 bond of FMN, is also likely to modulate their enzymatic activity.28, 51, 66 For 
instance, a co-crystal of nitroreductase NfsB (E. coli.) and nicotinic acid shows the possibility of 
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NAD to stack over an isoalloxazine ring in a proximal orientation for hydride transfer from C4 of 
the NAD ring to N5 of the FMN.66 Similar binding of substrate stacking above FMN was observed 
with dinitrodenzamide prodrugs and dicoumarol to an oxygen-insensitive nitroreductase NfsB,67 
binding of dicoumarol to flavin reductase (Vibrio fischeri)68 and coordination of benzoate to 
nitroreductase from Enterobacter cloacae.51 BluB, which shows the most structural similarity to 
IYD, holds its substrate, molecular oxygen, over the C4a-N5 bond of FMNhq.28 However, π-
stacking of 2IP above FMN and close proximity of the C–I bond to the C4a-N5 bond of FMN 
cannot mediate 2IP turnover. This observation indicated that IYD requires suitable substrates to 
modulate a switch of FMN chemistry for the deiodination reaction. 
 The human IYDI-Tyr structure showed that coordination of I-Tyr induces formation of a lid to 
generate a closed conformation of the I-Tyr–IYD complex. Binding of I-Tyr also triggers a side 
chain of Thr235 to move close to N5-FMN (3.1 Å) while Thr235 is away from N5-FMN in the 
human IYD without I-Tyr (4.9 Å) (Figure 3-2).32 This hydrogen bonding is key for promoting one-
electron chemistry in IYD and other related enzymes.28, 32, 52 The structure of hhIYDI-Tyr also 
exhibited the presence of an active site lid when I-Tyr is coordinated as observed in human IYDI-
Tyr. However, its equivalent Thr (Thr173) does not move to hydrogen bond with N5-FMN when 
I-Tyr is associated in the crystal structure. Instead, Thr173 presents in two different rotamers, both 
of which remain distal to the N5-FMN (3.6 – 4.0 Å) (Figure 3-6 A). The same orientations and 
distance of Thr173 to N5-FMN were observed in the structures of hhIYD and hhIYD2IP (Figure 
3-6 B). Rigidity of this region is likely introduced by the presence of Pro176,61, 62 which is replaced 
by Asn in both mouse and human IYDs. However, this Thr173 is still essential to promote one-
electron chemistry in hhIYD as evident by detection of FMNsq during the reduction of hhIYDF-
Tyr. In addition, the hhIYD T173A mutant also suppresses I-Tyr turnover while promoting a two-
electron process for reduction of a nitrotyrosine.52 Undetectable accumulation of FMNsq during 
reduction of hhIYD2IP confirmed the indispensability of the zwitterion for IYD catalysis. The 
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correlation between FMNsq stabilization and a hydrogen bonding of Thr173 to N5-FMN in hhIYD 
















Figure 3-6. Superposition of a loop containing Thr173 of hhIYD structures. The overlay of the 
Thr173 loop region of hhIYD in the absence of ligand (gray) with that of (A) hhIYDI-Tyr (blue) 
and (B) hhIYD2IP (green).  
 
3.5 Summary 
 Coordination of I-Tyr to hhIYD results in ordering of its active site lid through interactions 
between a substrate and active site residues in an arrangement similar to mammalian IYDs. 
However, I-Tyr is present in two conformations instead of a single conformation observed in mouse 
and human IYD. Crystallographic studies of hhIYD2IP exhibited the presence of mobile 2IP with 
a single orientation similar to the aromatic ring of I-Tyr in mouse and human IYD. Unlike I-Tyr, 
2IP lacks the ability to induce formation of the active site lid. The hhIYD2IP complex is likely 
stabilized by -stacking between 2IP and FMN and hydrogen bonding interactions from the 
phenolate to Ala64 and 2’OH-FMN. However, these interactions together with close proximity of 
the reaction position of the substrate (C–I bond) and the C4a-N5 bond of FMN are not sufficient to 
mediate IYD catalysis. The zwitterion of the substrate is key to induce closure of the active site lid 
and establish hydrogen bonding from the side chain of Thr to N5-FMN to promote the one-electron 
chemistry of FMN.  
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Chapter 4: Mutation of hhIYD to improve catalytic efficiency of turnover of 2-iodophenols 
4.1 Introduction 
 Slow turnover of 2IP by the wild-type hhIYD indicated that its catalytic machinery is still 
designed for deiodination of I-Tyr. However, its basal affinity for 2IP and related derivatives is 
high enough to encourage us to engineer the enzyme to improve dehalogenation of iodophenols for 
bioremediation. Due to the lack of hhIYD crystal structures at the time of engineering, three 
mutants were designed using a predicted hhIYD structure (Figure 4-1). The designs focused on 
modifications of amino acid residues located in an active site lid consisting of the C-terminus of 
αC and αD regions (Figure 4-1) to either enhance stability of the lid or coordinate to the substrate 
and FMN for modulating the FMN chemistry. The best knowledge available at the time of these 
studies was employed for each hhIYD mutant since engineering was conducted concurrently with 






















Figure 4-1. Predicted structure of hhIYD2IP (gray) generated using Phyre2 (see 4.2.1). 2IP and 
FMN are indicated in orange and yellow (carbon atoms) respectively. The structure was generated 
with a closed active site lid consisting of the C-terminus of αC helix and αD helix.  
 
 Mutations of hhIYD were performed before we learned that substrate affinity is not the only 
determinant for IYD catalysis. Hence, our first aim was to increase active site affinity to potentially 
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improve IYD catalysis for 2-iodophenols. The first double mutation (mutant A: hhIYD A64F 
L107A) was generated to introduce a possible π-stacking above 2IP to improve affinity for the 
substrate. A64 was selected for mutation as it is located over 2IP (Figure 4-2 A). Although A64 is 
conserved in most IYD homologs and was considered one of the signature residues for deiodinase 
activity,30 substitution of this Ala by Met in pfuIYD suggests that the conserved Ala is not necessary 
for IYD function (Figure 4-2 B).31 Introduction of A64F created a potential π-stacking above the 
substrate 2IP and is also likely to increase the population of the closed lid conformation by 
establishing hydrophobic interactions with a number of hydrophobic residues  (M99, W103, 
L107A, A64F and F110) located on αD region (Figure 4-2 B). Closure of the active site lid possibly 
mediates IYD catalysis toward iodophenols. L107A was introduced to avoid its potential steric 


























Figure 4-2. Predicted hhIYD structures (gray). (A) wild-type hhIYD and (B) hhIYD A64F L107A (mutant 
A). 2IP and FMN are presented in orange and yellow (carbon atoms) respectively. Mutated residues are 
highlighted in pink (carbon atom). (C) sequence alignment of IYD homologs exhibited a selected mutation 




 Our second goal was to stabilize the lid region to potentially mimic a closed conformation of 
the lid as it appears in hhIYDI-Tyr even though the coordinated substrate does not contain a 
zwitterion. The second mutant was designed to stabilize the C-terminus of the αC region to 
potentially induce an active site lid closure. To pursue this goal, a triple mutant (mutant B: hhIYD 
S94D N96R S175H) was created (Figure 4-3 A). N96R has the potential to establish an electrostatic 
interaction with Glu93. In addition, a positive charge introduced by N96R is likely to neutralize a 
negative dipole at the C terminus of its alpha helix (Figure 4-3 A).69 These interactions potentially 
enhance the helix stability. Another pair of mutations was inspired from inter-chain interactions 
observed in BluB, which has the greatest structural similarity to IYD (Figure 4-3 B).24, 28 Sequence 
and structural alignment of BluB and IYD revealed that BluB has the same active site lid position 
as that of IYD. However, the lid of BluB is always ordered whereas lid formation for IYD requires 
association of a zwitterionic substrate.24, 28 Stability of the BluB active site lid is in part likely made 
by a number of inter-helix interactions (Figure 4-3 B). To add an inter-chain interaction to IYD, 
S94D and S175H were introduced to create mutant B (Figure 4-3). These intra- and inter-chain 
interactions in mutant B are intended to stabilize the C-terminus of the αC so that it can be 
structured upon coordination of 2IP. Enhanced stability of the C-terminus of αC was thought to 
possibly induce closure of αD via hydrophobic interactions between a hydrophobic substrate, 2IP, 
















































Figure 4-3. Predicted structure of mutant B, hhIYD S94D N96R S175H, and structure of BluB. Cartoon 
illustration of (A) predicted hhIYD S94D N96R S175H structure (gray) and (B) BluB structure (PDB: 2ISJ) 
(yellow). Mutated residues are highlighted in pink. 2IP and FMN in hhIYD are presented in orange and 


















Figure 4-4. Predicted structure of mutant B, hhIYD S94D N96R S175H, exhibiting potential hydrophobic 
interactions among αD lid residues, A64 and 2IP. Mutated regions are highlighted in pink. 2IP and FMN are 
presented in orange and yellow (carbon atoms) respectively. 
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 The last hhIYD mutant (mutant C: hhIYD E91R) was designed for a 2IPCOOH substrate by 
replacing a potentially repulsive force between E91 and the carboxylate group of 2IPCOOH with 
an attractive polar interaction with Arg (Figure 4-5). In addition, E91R is also likely to interact with 
FMN to possibly improve IYD catalysis for iodophenol compounds. As shown by some enzymes 
within the nitro-FMN reductase superfamily, the chemistry of FMN co-factor is controlled by 
coordination of amino acid sidechains to FMN.51, 66, 68, 70-73 IYD is no exception. Coordination to 
N3- and O4-FMN in IYD is established through the zwitterion of the substrate.24, 32 Introduction of 
E91R potentially provides a polar interaction with the O4-FMN (Figure 4-5 B). Even though E91 
is one of the three active site lid residues assisting formation of the active site lid in a native hhIYD, 
this residue may not be necessary for a non-zwitterionic substrate like 2IPCOOH. R91 has the 
potential to mediate binding orientation of 2IPCOOH substrate, also coordinate O4-FMN to 













Figure 4-5. Active site region of the predicted hhIYD2IPCOOH structures. (A) wild-type hhIYD 
and (B) mutant C, hhIYD E91R. A mutated residues E91R is highlighted in dark pink. 2IPCOOH 
and FMN are presented in light pink and yellow (carbon atoms) respectively. 
 
 In this Chapter, we used rational design to generate three hhIYD mutants as described above. 
Kinetic studies of the mutants describe their catalytic efficiency (kcat/Km) as well as their kcat and 




4.2 Experimental Procedures 
4.2.1 Materials 
The predicted structure of hhIYD was generated by Phyre2 intensive search74 using an amino acid 
sequence of hhIYD as an input to provide its predicted structure in an apo monomer form. An apo 
biological dimer was then generated by Rosetta275 using C2 symmetry extracted from the structure 
of mouse IYDI-Tyr (PDB: 3GFD)24 (Calculation was performed by Dr. Michael Pacella, a former 
student in Dr. Jeffrey Gray’s lab). The resulting dimer was aligned with the mouse IYDI2-Tyr 
structure (PDB: 3GH8) and a predicted hhIYD structure with the most similar folding to 3GH8 was 
selected. Coordinates of FMN and I2-Tyr from PDB: 3GH8 were then merged with the predicted 
protein to create a hhIYD dimer in the presence of FMN and I2-Tyr. hhIYD2IP was generated by 
deleting the zwitterion and one iodo atom from I2-Tyr, hence providing the predicted hhIYD2IP 
complex. This resulting structure was used for the rational designs described above (Figure 4-1). 
Point mutations generated in the model were introduced using the mutagenesis feature in PyMOL 
without further optimization by Rosetta2. 
 Other materials are described in Chapter 2 (2.2.2). A detailed procedure for synthesis of 
2IPCOOH is described in Chapter 2 (2.2.6).  
4.2.2 Site-directed mutagenesis 
 Site-directed mutagenesis was performed as described in Chapter 2 (2.2.4) except for the 
modification of templates and primers described below. Vectors containing the hhIYD gene 
alternatively with SUMO (pSMT3-His6-SUMO-hhIYD-His6) and without SUMO (pET24a-
hhIYD-His6) were employed as the templates for site-directed mutagenesis. Each mutation was 
sequentially introduced using specified primers in the order provided below. The vectors with 
correct sequences after each round were used for the next round of a PCR reaction to introduce the 
next mutation to the templates. For mutant A, A64F was generated using a forward primer of 5'-
CTCAA-GGCACCTTCAGGTTTTCACAAACAGCCTTGGACCT-3' and its reverse com-
54 
 
plement. L107A was introduced after A64F by using a forward primer 5'CATGTCCAATG- 
AGTGGCTGGAAGATGCGCAGCCTTTTGGAA-3' and its reverse complement. For mutant B, 
S94D was first introduced using a forward primer 5'-GACAAGCTGCTGAAAAAGAGGAATTT- 
GAAGATTATAATGGCCGCATGTCCA-3' and its reverse complement. Then S175 was 
generated using a forward primer 5’-GTTTGGTGGCACTTACACATACCCCGCACCCAA- 
TGAATTTTTTGCAAAAAATT-3’and its reverse complement. Lastly, N96R was generated using 
a forward primer 5'-GCTGAAAAAGAGGAATTTGAAGATTATCGTGGCCGCATGTCCA-3' 
and its reverse complement. Note that a sequence of the forward primer GAT was modified from 
the wild-type hhIYD gene to maintain the previously introduced S94D mutation. For mutant C, 
E91R was created using a forward primer 5’- CGACAAGCTGCTGAAAAAGAGAGATTTG- 
AAAGCTATAATGGCCG-3’ and its reverse complement. The mutated codons are indicated in 
red. 
4.2.3 General methods 
 Expression and purification of the hhIYD mutants were performed following the procedures 
described in Chapter 2 (2.2.5). Concentration and FMN occupancy of each hhIYD mutant were 
measured following the method used for the wild-type hhIYD as described in Chapter 2 (2.2.2). 
Binding affinity of ligands for hhIYD was determined by their ability to quench the fluorescence 
of FMNox described in Chapter 2 (2.2.8). Catalytic deiodination of I-Tyr, 2IP and 2IPCOOH by 
hhIYD was quantified by formation of the deiodinated product after separation by the reverse-phase 
HPLC as described in Chapter 2 (2.2.9). 
4.3 Results 
4.3.1 Generation of the predicted hhIYD structure 
 Phyre2 intensive search initially provided 20 predicted structures of hhIYD based on 20 
different models from the PDB data base. A predicted structure that had the closet folding to the 
model (mouse IYDI2-Tyr, PDB: 3GH8) was selected for engineering studies. The resulting 
structure appeared as an apo monomer with its active site lid in a closed position. This was 
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employed to generate a biological dimer form. The final predicted hhIYD dimer in the presence of 
FMN and 2IP is superimposable with the crystal structure of mouse IYDI2-Tyr (PDB: 3GH8 with 
RMSD of 1.83 Å for 369 Cα atom comparison) and its crystallographic structure, hhIYDI-Tyr 
(PDB: 57O8 with RMSD of 1.37 Å for 367 Cα atom comparison).  
4.3.2 Site-directed mutagenesis 
 All of the mutated codons were successfully generated except for introduction of N96R to the 
pSMT3-His6-SUMO-hhIYD S94D S175H His6 vector. Only a partial primer insertion was detected 
from the sequencing results. A successful hhIYD S94D N96R S175H mutant without SUMO fusion 
was used for protein expression and further kinetic studies. 
4.3.3 Expression and purification 
 The hhIYD A64F L107A and hhIYD S94D N96R D175H triple mutants were expressed and 
purified with SUMO tag to yield 18 – 19 mg protein per 1 L of culture with FMN occupancy of 93 
– 98%. The hhIYD E91R mutant was expressed and purified without the SUMO fusion and yielded 
~13 mg protein per 1L of culture with ~92% FMN occupancy. Each mutant was obtained with 














Figure 4-6. SDS-PAGE gels of the purified wild-type hhIYD and its mutants. Lane 1 is a marker 
with molecular weights of protein (kDa) indicated on the left. Lane 2 is wild-type hhIYD. Lane 3 
is mutant A (hhIYD A64F L107A). Lane 4 is mutant B (hhIYD S94D N96R S175H). Lane 5 is 




4.3.4 Affinity of I-Tyr and 2IP for the wide-type hhIYD and mutant A 
 Binding affinity was determined by monitoring fluorescence quenching of the FMNox upon 
association of the ligand. Studies were performed at pH 9.0 to enhance population of the phenolate 
anion, which has preferential binding to IYD.32 The Kd of 2IP for mutant A is ~2 fold more than 
that of the wide-type while its Kd for I-Tyr is ~ 4-fold less (Table 4-1, Appendix Figure C1). The 
results revealed that affinity of the mutant A for 2IP cannot be improved indicating that a necessity 
of the zwitterion is still needed for binding to this mutant. 
Table 4-1. Binding affinity of I-Tyr and 2IP for a wild-type hhIYD and mutant A 
hhIYD 
Kd a (µM) 
2IP I-Tyr 
WT 14 ± 3 3.6 ± 0.5 
A64F L107A 32 ± 2 0.9 ± 0.2 
aDetermined from the data of Appendix Figure C1. Errors derived from least squares fitting. 
 
4.3.5 Catalytic deiodination of I-Tyr, 2IP and 2IPCOOH by hhIYD mutants 
 The initial rates of deiodination of I-Tyr, 2IP and 2IPCOOH by hhIYD mutants as a function of 
substrate concentrations were used to determine the steady-state kinetic parameters as shown in 
Table 4-2 (Appendix Figures A8 and C2-C4). The mutant A showed almost 3-fold decrease in a 
kcat/Km compared to that of the wild-type hhIYD (Table 4-2, Appendix Figure C2). The kcat value 
of deiodination of 2IP by mutant A is almost 2.5-fold lower and its Km is ~1.2 fold higher than that 
of the wild-type. The kcat of the mutant B for 2IP is also ~9 fold lower as compared to that of the 
wild-type. However, the mutant B has a lower Km for 2IP turnover by ~3 fold leading to the same 




















aDetermined from the data of Appendix Figure A8. bDetermined from the data of Appendix Figure C2 – C4. 
Errors derived from least squares fitting. 
 
 Deiodination rates of 2IPCOOH were first performed with mutant C that was designed to 
improve 2IPCOOH turnover. However, mutant A and B were also screened for their deiodinase 
activity for this substrate. The results demonstrated the kcat values of three mutants for 2IPCOOH 
ranged between 0.01 – 0.07 min-1 which is 3 – 10 fold less than that of the wild-type hhIYD (Table 
4-2, Appendix Figure A8 and C3). The Km values of mutant A and B increased significantly by ~2 
– 3 fold, resulting in decreases in kcat/Km by one order of magnitude as compared to that of the wild-
type enzyme. However, the Km for the mutant C is lower than that of the wild-type by 4 fold, leading 
to the kcat/Km within the same order of magnitude but ~3-fold lower than that of the wild-type. 
 Lastly, kinetics studies of the mutant A for I-Tyr were performed to learn whether its stronger 
affinity for I-Tyr than that of the wild-type hhIYD would increase its catalytic efficiency. The 
results exhibited that the both kcat and Km of mutant A decreased by ~2 fold compared to that of the 
wild-type. Hence, its kcat/Km for I-Tyr is almost identical to that of the wild-type hhIYD (Table 4-
2, Appendix Figures A8 and C4).  
4.4 Discussion 
 Decreases in affinity of 2IP for mutant A compared to that of the wild-type may result from 
steric hindrance of F64 that was introduced to the active site instead of the hope for adding π-
stacking to 2IP. Increases in affinity of mutant A for I-Tyr compared to the wild-type may result 









WTa 2IP  0.17 ± 0.02   4,100 ± 800 (4 ± 1) x 10-5 
mutant Ab  0.07 ±0.01 5,000 ± 2,000 (1.4 ± 0.6) x 10-5 
mutant Bb    0.02 ± 0.003   1,400 ± 700 (1.4 ± 0.8) x 10-5 
WTa 2IPCOOH 0.186 ± 0.006   7,100 ± 600 (2.6 ± 0.2)×10-5 
mutant Ab  0.027 ± 0.007 17,000 ± 9,000 (1.6 ± 0.9)×10-6 
mutant Bb  0.07 ± 0.03 20,000 ± 10,000 (3.5 ± 2.3)×10-6 
mutant Cb  0.0152 ± 0.0005   1,700 ± 200  (0.89 ± 0.01) x 10-5 
WTa I-Tyr        16 ± 1        12 ± 2      1.3 ± 0.3 
mutant Ab           7 ± 1 6 ± 2      1.2 ± 0.4 
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possible bulkiness introduced by F64. However, the ~ 4-fold tighter affinity of mutant A for I-Tyr 
than that of wide-type still could not improve its catalytic efficiency as evident by almost identical 
kcat/Km values. This finding also supports the knowledge learned in Chapter 2 that tight binding 
does not ensure efficient catalysis. 
 Three ways to improve the kcat/Km for an enzymic transformation are to increase the kcat and/or 
decrease the Km value. For mutant A, the kcat for deiodination of 2IP is 2.4 fold lower while the Km 
is only 1.2 fold higher compared to that of the wild-type, leading to ~ 3 fold lower kcat/Km. Catalysis 
of 2IP by mutant A may be in part suppressed by its weaker affinity compared to the wild-type. 
The decrease in catalytic efficiency of 2IPCOOH by mutant A is even more drastic than 2IP 
compared to the wild-type as the kcat for deiodination of 2IPCOOH by mutant A is ~7 fold lower 
and its Km is ~ 2.4 fold higher than that of the wild-type leading to ~17 fold decrease in kcat/Km. In 
addition to possible steric hindrance introduced by F64, the increase in Km and significant decrease 
in the kcat/Km of 2IPCOOH for mutant A may be explained by a repulsive force between the 
carboxylate of 2IPCOOH. This rationale is supported by smaller changes of the kinetic parameters 
for deiodination of 2IP by mutant A compared to those of 2IPCOOH. 
 For mutant B, its kcat for deiodination of 2IP is 8.5 fold lower but the Km is only ~3 fold lower 
compared to those of the wild-type. This change leads to ~ 3 fold lower kcat/Km than that of the 
wild-type. The reason for a decrease in catalysis of 2IP by mutant B is not known but we can 
speculate that either the C-terminus of the αC is not stabilized or it is stabilized but cannot serve 
FMN chemistry for deiodination. The kcat of 2IPCOOH turnover by mutant B is ~ 2.7 fold lower 
while its Km is almost 3 fold higher than that of the wild-type. This mutation resulted in almost 8-
fold decrease in the kcat/Km. Again, the increase in the Km and decrease in the kcat/Km for 
deiodination of 2IPCOOH by mutant B compared to the wild-type can be explained by a repulsive 
force between E91 and the carboxylate of 2IPCOOH. Kinetic studies of mutant C confirmed 
impaired catalysis caused by this repulsion as an introduced favorable interaction from E91R can 
decrease the Km for deiodination of 2IPCOOH by ~ 4 fold compared to the wild-type. However, 
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the kcat of 2IPCOOH by mutant C significantly drops by ~12 fold compared to that of the wild-type 
leading to ~3 fold lower kcat/Km. Significant decrease in the kcat of deiodination of 2IPCOOH for 
mutant C implied that R91 may result from an electron withdrawing effect as evident by 10 fold 
greater kcat/Km for deiodination of 4-amino-2-iodophenol (4A2IP) by the wild-type hhIYD 
compared to that of 2IPCOOH. However, this cannot be concluded until the related studies are 
established. 
4.5 Summary 
 The Kd of mutant A for 2IP is increased by ~2 fold while that of I-Tyr is decreased by ~4 fold 
compared to those of the wild-type hhIYD. We speculated that F64 may introduce steric hindrance 
to the active site, hence impair its affinity and catalysis for 2IP. However, the zwitterion is likely 
to assist binding of I-Tyr despite the presence of bulky F64. Again, improved affinity of I-Tyr for 
mutant A does not provide more efficient catalysis which confirmed that tight binding is not the 
only determinant for IYD catalysis. The kcat/Km values of 2IP and 2IPCOOH turnover by mutant 
A-C are generally lower than those of the wild-type. More profound decrease in kcat/Km and increase 
in Km were observed in deiodination of 2IPCOOH compared to 2IP. This difference may be 
explained by repulsive interaction between E91 to the carboxylate of 2IPCOOH. This interaction 
also exists in the wild-type hhIYD. However, introduced mutations may not be favorable for 
catalysis of 2IPCOOH, hence deiodination of 2IPCOOH is even suppressed compared to the wild-
type. However, decrease in the Km of 2IPCOOH turnover for E91R mutant is likely explained by a 
favorable interaction between the substrate and R91. There is a similar observation from the studies 
of Drosophila IYD showing significant increase in the Km of deiodination of I2-Tyr by E154Q.23 
The increase in Km is potentially due to removal of favorable electrostatic interaction between 
Glu154 and the zwitterion of I2-Tyr. The studies indicated that Glu91 of hhIYD is potential for 





Chapter 5: Analysis of IYD-related enzymes for affinity of 2-halophenols 
5.1 Introduction 
 Sequence analysis identified IYD as a member of the nitro-FMN reductase superfamily which 
supports diverse redox reactions of varied substrates.20, 76 Diversity of enzymatic reactions in the 
superfamily implied opportunities to develop other IYD-related enzymes to possess deiodinase 
activity. Here we studied two additional enzymes in the nitro-FMN reductase superfamily, BluB 
and 3EO8, to explore the possibility of developing deiodinase activity from their scaffold. 
 The BluB gene was previously identified in bacterium Sinorhizobium meliloti and found 
necessary for biosynthesis of a lower ligand of vitamin B12.28, 77 Determination of the first crystal 
structure of mouse IYD demonstrated that BluB has the most structural similarity to IYD (RMSD 
of 4.89 Å for 283 Cα atom comparison of PDB: 3GFD and 2ISJ) (Figure 5-1).24, 28 Sequence 
alignment shows BluB and IYD share an active site lid derived from the same region of their 
primary structures (Figure 5-2 A), which is different from the other two subclasses (NOX and 
FRP).24 Hence, BluB and IYD were placed into a new distinct subclass in the superfamily.24 
Structural analysis revealed that the lids of BluB and IYD are located in similar orientations, 
however the loop of BluB aligns in a different orientation from that of IYD as its loop is more 
buried into the active site to potentially accommodate only the small size of molecular oxygen 














Figure 5-1. Superposition of BluB and IYD structures. Overlay of BluB (PDB 2ISJ) (purple) with 





Figure 5-2. Sequence and structural comparison between mouse IYD and BluB. (A) amino acid 
sequence alignment of an active site lid region in mouse IYD and BluB. Numbers on the left and 
right indicate numbering for amino acid residues. Conserved residues are indicated in red. (B) 
superposition of mouse IYD (PDB 3GFD) (dark blue) and BluB (PDB 2ISJ) (purple). Figure on 
the right demonstrates the lid (αC and αD) and loop regions of mouse IYD (dark blue) and BluB 
(purple). FMNox and I-Tyr are presented in yellow and blue (carbon atoms) respectively.   
 
 Besides the structural similarity of BluB and IYD, they also exhibit the same one-electron 
mechanism as evident by consumption of molecular oxygen by BluB and detection of a FMNsq 
intermediate in the presence of zwitterionic substrate or ligand in IYD.22, 28, 32, 52 In addition, a side 
chain of Ser167 in BluB always provides a hydrogen bonding to N5-FMN that assists stabilization 
of the one electron process. This observation is borne out by similar distance between Ser167 to 
both N5-FMNox and N5-FMNhq (3.2 – 3.4 Å) (Figure 5-3).28 In contrast, this equivalent hydrogen 
bonding is not formed in IYD unless the zwitterionic substrate is bound.32 The intact hydrogen 
bonding to N5-FMN in BluB suggest that the scaffold of BluB may be able to stabilize one-electron 
chemistry for deiodination of iodophenols. Moreover, the crystal structure of BluB with reduced 
FMNhq and molecular oxygen also showed that an oxygen is aligned above the reactive site C4a-
N5 bond equivalent to alignment of C–I bond of I-Tyr in a structure of IYD (Figure 5-4), which 
suggests that BluB and IYD have similar reaction sites.24, 28, 32 Moreover, success in engineering 
BluB for IYD activity may provide an additional benefit to exploit a known reductase (SsuE) for 



















Figure 5-3. Superposition of the structures of FMNhq-bound BluB in the presence of oxygen (PDB 
2ISL) (orange) and FMNox-bound BluB (PDB 2ISJ) (purple). FMNhq and FMNox are presented in 
orange and purple (carbon atoms) respectively. Oxygen is indicated in red. This structural 





















Figure 5-4. Similar alignment in substrates of BluB and IYD over a highly reactive center C4a–
N5 bond of FMN. Alignment of the substrates (A) oxygen (red) and (B) C–I bond of I-Tyr (blue) 
of BluB and IYD above C4a–N5 bond of FMNhq (pink) and FMNox (blue) respectively.  
 
 The second enzyme (Hub enzyme, PDB 3EO8) was selected based on a new classification for 
the nitro-FMN reductase superfamily. Recently, Babbitt and Copp et al. developed an exhaustive 
analysis of the entire FMN-dependent nitroreductase (NTR) superfamily using new integrative 
approaches to examine protein sequence, structure and function for comprehensive functional and 
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sequence evolutionary relationship.78 Analysis of a large sequence set resulted in 22 major 
subgroups including BluB, IYD and a new central Hub topology directly connecting to most of 



















Figure 5-5. Cytoscape79 demonstrating a representative sequences similarity network (SSN)80, 81 of 
the nitroreductase superfamily. A total of 24,270 protein sequences are depicted by 5,337 nodes 
that represent proteins sharing >60% sequence identity using a stringency threshold value of e-18. 
Node coloring represents subgroup classification including IYD (magenta), BluB (dark blue) and 
Hub (red) subgroups. Figure was adapted from Babbitt and Copp et al.78 
 
 The hub subgroup may represent an ancestral origin for contemporary NTR as most enzymes in 
the hub subgroup are from bacteria (88 %) and archaea (9 %).78 Structural analysis revealed most 
of the hub enzymes display a minimal scaffold that is conserved throughout other NTR. The 
structures of BluB and IYD also represent this general minimal scaffold with additional insertions 
(active site lid) required for their specific activities.24, 28, 78, 82 Analysis from Copp et al. indicated 
that 3EO8 is a hub protein that exhibits the closest structural similarity to IYD with RMSD of 3.62 
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Å for 221 Cα atom comparison of PDB: 3EO8 versus 3GFD (Figure 5-6). This enzyme has a crystal 
structure available (PDB 3EO8) that was annotated as a BluB-like enzyme, however, its actual 
biochemical function is still unknown. 3EO8 possesses an active site lid that is derived from the 
same region in its primary structure as that of IYD (Figure 5-7 A), but superposition of the 3EO8 
and mouse IYD structures shows their different lid orientations (Figure 5-7 B). Moreover, the loop 
of 3EO8 is extended more than that of IYD by having two extra helices pointing away from its 












Figure 5-6. Superposition of 3EO8 and IYD structures. Overlay of 3EO8 (PDB 3EO8) (pink) with 



























Figure 5-7. Sequence and structural comparison between mouse IYD and 3EO8. (A) amino acid 
sequence alignment of an active site lid region in mouse IYD and 3EO8. Numbers on the left and 
right indicate numbering for amino acid residues. Conserved residues are indicated in red. (B) 
superposition of mouse IYD (PDB 3GFD) (dark blue) and 3EO8 (PDB 3EO8) (pink). Figure on 
the right demonstrates the lid (αC and αD) and loop regions of mouse IYD (dark blue) and 3EO8 
(pink). FMNox and I-Tyr are presented in yellow and blue (carbon atoms) respectively.   
 
 The structure of 3EO8 also suggested the possibility that 3EO8 supports one-electron chemistry 
since the side chain of Thr163 is likely to provide a hydrogen bonding to N5-FMN similar to that 
observed in BluB and IYDI-Tyr (Figure 5-3 and 5-8).24, 28, 32 Structural analysis of 3EO8 with 
placement of 2IP (see 5.2.1) demonstrated that the 2IP3EO8 complex may be stabilized by similar 
interactions observed in the hhIYD2IP complex (Figure 5-9). However, the active site of 3EO8 is 
relatively small compared to IYD suggesting that the wild-type 3EO8 may not be able to 
accommodate 2IP. Mutations in the active site region of 3EO8 are necessary to allow more access 




















Figure 5-8. Orientation of a side chain of Thr toward N5-FMN in structures of (A) 3EO8 (PDB 
3EO8) (pink) and (B) mouseI-Tyr (PDB 3GFD) (dark blue). FMN and I-Tyr are presented in 












Figure 5-9. Possible interactions stabilizing 2IPFMN complex in (A) 3EO8 (PDB 3EO8) (pink) 
and (B) IYD (PDB 3GFD) (dark blue). Dashed lines indicated hydrogen bonding distance within 
2.7 – 2.8 Å. FMN and 2IP are presented in yellow and orange (carbon atoms) respectively. 
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 In this chapter, the possibility of introducing deiodinase activity into BluB and 3EO8 is 
evaluated by screening affinity of 2IP for both wild-type enzymes. Eight individual 3EO8 mutants 
were generated in the hope of enlarging space in its active site for accommodation of 2IP. Affinity 
of 2IP for all 3EO8 mutants was also screened to determine the contribution from each mutation to 
affinity with 2IP. 
5.2 Experimental Procedures 
5.2.1 Materials 
 The plasmid encoding BluB gene (pET-11t/BluB–His8) was kindly provided by Dr. M. E. Taga 
(UC Berkeley, Berkeley, CA). The enzyme SsuE was kindly provided by Dr. H. R. Ellis (Auburn 
University, Auburn, AL). DH5α E. coli. cells containing pSpeedET-wild-type 3EO8 gene was 
obtained from the DNASU plasmid respository (Arizona State University, Tempe, AZ). NADH 
and NADPH were obtained from Sigma-Aldrich. Other materials are listed in Chapter 2 (2.2.1). A 
3EO82IP complex was generated in Coot57 by transfering 2IP coordinates from hhIYD2IP 
structure (PDB 5KRD) to a structure of 3EO8 (PDB 3EO8). 
5.2.2 Site-directed mutagenesis of 3EO8 protein 
 Site-directed mutagenesis of 3EO8 was performed following the protocol described in Chapter 
2 (2.2.4) with the templates and primers listed below. A vector containing wild-type 3EO8 gene 
(pSpeedET-His6-3EO8) (Appendix Figure D1) was initially employed as a template for site-
directed mutagenesis. Then, additional mutation(s) was sequentially introduced using specified 
primers provided below. Each resulting vector with correct mutation(s) was then used for the next 
round of a PCR reaction to introduce the next mutation. A total of 8 individual 3EO8 mutants were 
created with mutation(s) introduced to the 3EO8 gene in an order indicated in Table 5-1.  F88A 
was generated using a forward primer 5’-GGCTAATAGATTTAGAAAAGCTGTTAAAAATTT-
TACAC-3’ and its reverse complement. F92A was generated using a forward primer 5’-GAAAA- 
TTTGTTAAAAATGCTACACTATTTTACTTAAAAGC-3’ and its reverse complement. F88A 
F92A were simultaneously introduced using a forward primer 5’-GGCTAATAGATTTAGAAAA- 
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GCTGTTAAAAATGCTACACTATTTTAC-3’. Y110H was generated using a forward primer 
5’GTTTTTACAAAGGTACATAATCCATCAGG-3’ and its reverse complement. S113A was 
created using a forward primer 5’- TAATCCAGCAGGATATTATGAATTAG-3’ and its reverse 
complement. K40A was introduced to a template using a forward primer 5’- CAGCACCATCAG-
GCGCGAATATTCAA-3’ and its reverse complement. K40Y was generated using a forward 
primer 5’-GCACCATCAGGC- TATAATATTCAAAAC-3’ and its reverse complement. The last 
mutation, Y110S was generated using a forward primer 5’-GTTTTTACAAAGGTAAGTAATCC-
ATCAGG-3’ and its reverse complement. The mutated codons are indicated in red. 




3 F88A F92A 
4 F88A Y110H 
5 F88A Y110H S113A  
6 F88A Y110H K40A 
7 F88A Y110H K40Y 
8 F88A Y110S 
 
5.2.3 Expression and purification of BluB and 3EO8 enzymes 
 BluB was expressed and purified with a method modified from the previously reported 
procedure.77 Electrocompetent BL21 E. coli. cells were transformed with an expression construct, 
pET-11t/BluB–His8. Single colonies were picked and inoculated into a seed culture of LB medium 
(25 ml) containing ampicillin (50 μg/ml). The culture was incubated with shaking at 37 oC for ~14 
h. The seed culture was then diluted by 50-fold into an expression culture of LB medium (1 L) with 
ampicillin (50 μg/ml). The expression culture was shaken at 37 oC until OD600 of 0.9-1.0 was 
reached. Protein expression was performed by addition of IPTG (300 µM) with shaking for ~3 h at 
37 oC. The induced cells were then harvested by centrifugation (5,000 x g for 10 min). Cell pellets 
were washed with buffer (300 mM NaCl, 50 mM sodium phosphate pH 8.0), frozen in liquid 
nitrogen and stored at -80 oC.   
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 For purification, frozen cells were re-suspended in the same buffer and DNaseI (10 μg/ml), 
phenylmethylsulfonyl fluoride, PMSF (1 mM) and pepstatin A (10 μg/ml) were added. The cells 
were lyzed using Emulsiflex C3 homogenizer (Avestin) at pressure of 15,000 – 20,000 psi for 3 – 
4 passages. Cell lysates were centrifuged at 57,000 x g for 1 h to precipitate cell debris. BluB was 
purified using Ni-NTA affinity with a flow rate of 1 ml/min. The supernatant (25 – 35 ml) was 
loaded onto a Ni-NTA column (7 ml) that was pre-equilibrated with the lysis buffer containing 20 
mM imidazole (3 column volumes). The loaded sample was washed with lysis buffer containing 
20 mM and 60 mM imidazole for 5 column volumes each before protein was eluted with lysis 
buffer containing 250 mM imidazole. The eluted fractions with > 95% purity were combined and 
dialysed three times (4 h, 4 h and 12 – 14 h) in dialysis buffer (50 mM NaCl, 50 mM sodium 
phosphate, pH 8) with 1:100 of protein to buffer volume (10 % glycerol was added into the final 
dialysis buffer). BluB was then concentrated using an Amicon ultra centrifugal filter unit with a 10 
kDa cut-off. The final concentration of BluB was determined by measuring A280 using ε280 = 44,710 
M-1cm-1 as determined by ExPASy ProtParam.34 
 3EO8 protein (Appendix Figure D2) was expressed and purified following the procedure used 
for IYD described in Chapter 2 (2.2.5). Only induction conditions were modified by increasing 
IPTG concentration from 20 µM to 40 µM and increasing the induction temperature from 16 oC to 
20 oC but the same induction time was used (12-16 h). Purified protein was concentrated and its 
concentration was determined following the procedure described in Chapter 2 (2.2.2). 
5.2.4 BluB activity assay 
 Native activity of BluB was tested by monitoring FMN depletion (445 nm) in the presence of a 
FMN reductase enzyme (SsuE) and NADPH as previously described.77  
5.2.5 Binding affinity of BluB for FMN and 2IP  
 Determination of Kd values of BluB for FMN and 2IP was performed using an isothermal 
titration calorimetry (ITC) by measuring thermal energy associated with ligand binding. Affinity 
assays of BluB for FMN were carried out following a method previously described.28 In brief, BluB 
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solution (25 µM, 1.5 ml) was loaded into a sample cell while degassed FMN (500 µM) was loaded 
onto an injection syringe. An apo-BluB was then titrated with 10 µl of FMN for 25 injections. The 
experiment was performed in buffer (10 mM NaCl, 10 mM Tris pH 8.0) at 23 oC using a Microcal 
MCS ITC at Integrated Imaging Center (IIC), Johns Hopkins, Homewood campus. 5 min-interval 
was allowed between each injection for heat generated to re-equilibrate. Under similar conditions, 
determination of BluB affinity for 2IP was performed by titration of 10 µl of degassed 2IP (3 mM) 
for 55 injections into BluB-FMN solution (1.5 ml) containing BluB (70 μM) and FMN (140 μM). 
The data were fit using Origin ITC software (V. 5.0, Microcal Software Inc.) and the result was 
modeled to a single binding site per monomer to determine the Kd value. 
5.2.6 NAD(P)H reduction assays  
 Reduction of FMNox bound to 3EO8 by NAD(P)H was determined by monitoring reduction of 
FMNox-bound 3EO8 (λ = 445 nm) in the alternative presence of NADH or NADPH. The protocol 
was modified from that previously described.77 The UV spectrum of buffer (300 mM NaCl, 0.5 
mM TCEP, 10 % glycerol, 50 mM sodium phosphate pH 7.4) containing NAD(P)H (10 mM) and 
3EO8 (20 µM) was monitored over 30 min using a Hewlett-Packard 8453 spectrophotometer. 
5.2.7 Binding affinity determination of 3EO8 protein for 2IP and 2FP 
 Binding affinity of 3EO8 for 2IP and 2FP was determined by the ability of the ligand to quench 
the fluorescence of FMNox in the active site of the protein (λex = 450 nm and λem = 529 nm). 
Fluorescence binding assays were performed following a procedure described in Chapter 2 (2.2.8). 
5.2.8 Oxygen sensitivity assays 
 Oxygen sensitivity of 3EO8 protein was determined by re-oxidation of reduced FMNhq bound 
to 3EO8 to generate FMNox (λ = 445 nm) upon reacting with molecular oxygen. Buffer (300 mM 
NaCl, 0.5 mM TCEP, 10 % glycerol, 50 mM sodium phosphate pH 7.4) containing 3EO8 protein 
(20 µM) was purged with Ar for 30 min and a head space was then purged for an addition 20 min 
to remove molecular oxygen. Subsequently, stoichiometric amount of dithionite in 5 % NaHCO3 
solution was gradually added to this protein solution until FMNox was fully reduced (decrease in 
71 
 
A445). The FMNhq bound protein solution was then exposed to O2 and mixed immediately followed 
by monitoring an increase in absorbance of FMNox (λ = 445 nm) every minute over 10 min. The 
solution was mixed again after every 5 min during the UV measurement. 
5.3 Results 
5.3.1 Expression and purification of BluB and 3EO8 
 BluB and all 3EO8 proteins were purified to homogeneity (Appendix Figure D3 – D4). Soluble 
BluB was expressed without a protein fusion in an apo form in a relatively high yield of 25 mg/L. 
3EO8 wild-type and its 8 mutants were also expressed without a SUMO fusion. FMN occupancy 
of all 3EO8 proteins was relatively consistent between 60 – 73 % except for mutant 8, which had 
a FMN occupancy of only ~48 %. Under the same expression conditions, most 3EO8 proteins were 
obtained with in good yield of 13 – 17 mg/L except for a 3EO8 wild-type, mutant 2 and 4, which 
provided relatively low protein yields (5 – 8 mg/L).  
5.3.2 Studies of a BluB enzyme 
 5.3.2.1 BluB activity 
 Native activity of BluB was first tested to ensure that the enzyme was active for further studies. 
Activity of BluB was determined by monitoring deletion of FMNox (λ = 445 nm).  The expected 



































Figure 5-10. FMN depletion by BluB. BluB activity assay was performed as previously described77 
at room temperature. Reaction contained 50 μM FMN, 300 μM NADPH, 50 μM BluB, and 200 
nM SsuE in 20 mM Tris–HCl, pH 8. Depletion of FMN was monitored over 10 min after the 
reaction was initiated by addition of SsuE reductase. Gradient of the spectrum (black to light gray) 
indicate decrease in maximum absorbance of FMNox at 445 nm. 
 
 5.3.2.1 Affinity of FMN and 2IP for BluB 
 Affinity of FMN and 2IP for BluB was determined by measuring thermal energy associated 
with ligand binding. Determination of FMN affinity to BluB was first performed to verify a 
protocol for the ITC experiment. The resulting Kd value and other thermodynamic parameters of 
FMN for BluB are in the same order of magnitude with those previously reported28 (Table 5-2, 
Appendix Figure D5-A) indicating a proper protocol for affinity was determined. Then, titration of 
2IP into the FMN-bound BluB solution was monitored to assess the ability of BluB to bind 2IP. In 
contrast to FMN, binding affinity of 2IP for BluB was not observed as exhibited by scattered plots 
of energy per injection versus molar ratio of 2IP (Appendix Figure D5-B). 
Table 5-2. Kd value and thermodynamic parameters of BluB for FMN 
Enzyme Kd a (µM) ∆Ha (kcal/mol) ∆Sa (cal/mol K) 
BluB 3.6 (1.6) -16.2 (-15.0) -29.6 (-23.6) 
aDetermined from the data of Appendix Figure D5-A. Parameters derived from a single experiment. Values 







5.3.3 Studies of 3EO8 proteins 
 5.3.3.1 NAD(P)H-dependent FMN reduction of 3EO8 
 Reduction of FMN-bound 3EO8 (WT) in the presence of  NAP(P)H was performed to determine 
if the hub 3EO8 protein is capable of catalyzing NAD(P)H-dependent FMN reduction. The result 
confirmed that 3EO8 (WT) lacks this ability as no depletion of FMNox-bound 3EO8 (WT) was 
observed when NAD(P)H was present (Figure 5-11). 
 
Figure 5-11. UV spectra during the reduction of 3EO8-FMNox in the presence of NAD(P)H. No 
depletion of 3EO8-FMNox by (A) NADH and (B) NADPH was observed at λ = 445 nm over 30 
min. Reactions containing buffer (300 mM NaCl, 0.5 mM TCEP, 10 % glycerol, 50 mM sodium 
phosphate pH 7.4), 10 mM NAD(P)H and 20 µM 3EO8 (WT) were performed at room temperature. 
  
5.3.3.2 Affinity to 2-iodophenol (2IP) and 2-fluorophenol (2FP) for the wild-type 3EO8 and 
its mutants 
 Affinity assays of 2IP and 2FP for the wild-type 3EO8 and its mutants were carried out to 
determine if affinity of 2IP and 2FP for the engineered 3EO8 proteins with higher active site 
accessibility was improved compared to that of the wild-type. Affinity was determined by 
monitoring quenching of the fluorescence of FMNox bound to the proteins upon coordination of 
2IP. Since incomplete fluorescence quenching due to the solubility limit of 2IP did not allow 
determination of the Kd values, binding affinity of 2IP for each 3EO8 protein was evaluated by % 
fluorescence quenching at ~ 10 mM 2IP. 
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 The results demonstrated that wild-type 3EO8 cannot bind 2IP (Figure 5-12). The increase in 
fluorescence emission at high concentration of 2IP (≥ 5 mM) is likely explained by the release of a 
bound FMN into the protein solution. The release of FMN is potentially caused by instability of 
the protein at high concentration of 2IP which may lead to partial protein unfolding. Affinity studies 
of the mutants with 2IP exhibited that only mutant 4, 5 and 8 display slightly decreases in F/F0 
compared to that of the wild-type (~ 10 – 20 % fluorescence quenching at ~10 mM 2IP) while other 


















Figure 5-12. Quenching of FMNox fluorescence in the presence of 2IP to wild-type 3EO8 and 8 
indicated mutants at 25 oC. 3EO8 (5 µM) in 100 mM potassium phosphate, pH 7.4 were stirred at 
25 oC for 30 min prior to addition of 2IP. Black solid lines mark at F/F0 = 1 and [2IP] = 10 mM for 
easy comparison of fluorescence intensity among different proteins. 
 
Affinity of 2FP for the wild-type 3EO8 and mutants 1-3 was determined to guide the next 
mutation for 3EO8 enzyme. The results showed that % fluorescence quenching at 10 mM 2FP is 
similar to that of 2IP at the same concentration but significant fluorescence quenching was observed 
for the wild-type and all 3 mutants at high concentration of 2FP (~40 – 60 % quenching at ~57 mM 
2FP) (Figure 5-13). As expected, the binding curves of 2FP to 3EO8 proteins were more 
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experimentally distinguishable than that of 2IP. The results showed that mutant 1 gained the most 
fluorescence quenching 60% at ~57 mM 2FP while the wild-type showed ~40% quenching. 
 
 
Figure 5-13. Quenching of FMNox fluorescence upon binding of 2FP to wild-type 3EO8 and 3 
indicated mutants at 25 oC. 3EO8 (5 µM) in 100 mM potassium phosphate, pH 7.4 were stirred at 
25 oC for 30 min prior to addition of 2FP. Black solid lines mark at F/F0 = 1 and [2FP] = ~57 mM 
for easy comparison of fluorescence intensity among different proteins. 
 
   5.3.3.3 Oxygen sensitivity of 3EO8 
 Oxygen sensitivity of the wild-type and 3EO8 mutant 6 (F88A Y110H K40A) with the greatest 
active site accessibility was determined by measuring re-oxidation of FMNhq after mixing the 
reduced protein with molecular oxygen. The results showed the increase of FMNox over time (6 
min) after the reduced enzymes were mixed with O2. This experiment indicated that 3EO8 is an 



























Figure 5-14. Oxidation of FMNhq-bound 3EO8 protein by oxygen. Oxidation of (A) FMNhq-bound 
3EO8 (WT) and (B) FMNhq-bound 3EO8 mutant 6 (F88A Y110H K40A) in the presence of oxygen. 
Buffer (300 mM NaCl, 0.5 mM TCEP, 10 % glycerol, 50 mM sodium phosphate pH 7.4) containing 
20 µM 3EO8 was purged with Ar to remove O2 prior to addition of ~ 20 µM dithionite. The solution 
was monitored at λ = 445 nm to observe increase of FMNox. Spectrum at time = 0 min (light gray) 
was recorded prior to mixing with O2. The solution was then mixed immediately after being 
exposed to O2 and the spectra were recorded continuously for every 1 min. Mixing was introduced 
every 5 min during the measurement. The selected spectra represent the data after the 1st mix (gray) 
and the 2nd mix (black) which demonstrates fully oxidized FMNox.  
 
5.4 Discussion  
 Binding studies revealed that a native BluB did not bind 2IP in its active site. The lack of binding 
of 2IP to BluB is consistent with its crystal structure exhibiting a loop of BluB that is more buried 
into its active site resulting in a small binding pocket to exclude bulky substrates larger than 
molecular oxygen (Figure 5-2 B). A wild-type 3EO8 also exhibited no detectable binding to 2IP as 
expected for its inaccessible and small active site (Figure 5-15 A-B). Hence, 8 3EO8 mutants were 
generated to either open its active site entrance or enlarge the active site volume to increase its 
possibility to bind 2IP (Figure 5-15 and 5-16). Mutant 1 (F88A) and 2 (F92A) modify the entrance 
of the active site to allow more access to 2IP (Figure 5-15 C-F). However, very minimal 
fluorescence quenching (~1-2 %) of mutant 1 and no detectable quenching of mutant 2 was 
observed at the end of 2IP titration (Figure 5-12). A combination of F88A and F92A still did not 
improve affinity with 2IP. Binding studies of 2IP for mutants 1 – 3 were not experimentally 
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distinguishable and were still limited by solubility of 2IP, further affinity assays with 2-
fluorophenol (2FP) for these three mutants were performed. 2FP was selected as its higher 
solubility than 2IP that allowed us to determine affinity of the ligand at higher concentrations (~57 
mM) compared to 2IP (~10 mM). The smaller fluoro atom also occupies less space than an iodo 
atom, hence 2FP is more likely to incorporate the active site of 3EO8 proteins better than 2IP. The 
results revealed that mutant 1 exhibited the greatest fluorescence quenching (62 %) among the three 























































Figure 5-15. Active site region of 3EO8 protein with a placement of 2IP. Active site region of (A-
B) 3EO8 (WT), (C-D) 3EO8 mutant 1 (F88A), (E-F) 3EO8 mutant 2 (F92A) and (G-H) 3EO8 
mutant 3 (F88A F92A). The active sites are shown in stick representation to exhibit mutation site(s) 
(left panel) and surface representation to exhibit active site accessibility (right panel). The native 
amino acid residues are shown in pink and the mutated residues are presented in gray (carbon 
atoms). FMN and 2IP are presented in yellow and orange respectively. 
 
 Y110 was selected as the next mutation site because it is located nearby the iodo atom of 2IP 
(Figure 5-16). Introduction of Y110H was thought to provide sufficient space for an iodo atom of 
2IP (4.2 Å) (Figure 5-16 A). Histidine was selected to maintain a possible halogen bonding to the 
iodo atom of 2IP as possibly provided by Y110 in the native protein (2.8 Å) (Figure 5-16 A). 
Binding affinity of mutant 4 to 2IP showed about ~10 % quenching (at 2IP ~ 10 mM) indicating a 
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little increase in affinity with 2IP compared to the wild-type. Another mutation site (S113A) close 
to C–I bond was also generated in combination with F88A Y110H (mutant 5: F88A Y110H S113A) 
(Figure 5-16 B), but a similar lack of fluorescence quenching to that of mutant 4 was observed. 
Two additional mutants were generated to allow more access for 2IP to enter the active site (mutant 
6: F88A Y110H K40A) or to introduce possible π-stacking interaction to potentially increase 
affinity with 2IP (mutant 7: F88A Y110H K40Y) (5-16 C-D). However, neither of these two 
mutants could increase the affinity for 2IP since no fluorescence quenching was observed at the 
end of the titration of (~10 mM 2IP) (Figure 5-12). As introduction of Y110H provided significant 
fluorescence quenching upon addition of 2IP, this mutation site was re-considered for the 

























































Figure 5-16. Active site region of 3EO8 with the placement of 2IP. Stick illustration of active site 
region indicating mutation sites of (A) mutant 4 (F88A Y110H), (B) mutant 5 (F88A Y110H 
S113A), (C) mutant 6 (F88A Y110H K40A), (D) mutant 7 (F88A Y110H K40Y) and (D) mutant 
8 (F88A Y110S). The native amino acid residues are shown in pink and the mutated residues are 
presented in gray (carbon atoms). FMN and 2IP are presented in yellow and orange respectively. 
 
 Initially, Y110H was thought to provide enough space for an iodo atom of 2IP as the nitrogen 
atom of His is quite distant from the iodo atom of 2IP (4.2 Å) (Figure 5-16 A). However, its affinity 
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for 2IP was only increased by 10 % at ~10 mM 2IP. Hence, another mutation with a further decrease 
in size (Y110S) was introduced into the 3EO8 F88A gene to generate mutant 8 (F88A Y110S) 
(Figure 5-16 E). Binding assays of mutant 8 with 2IP showed more fluorescence quenching (~20% 
at ~10 mM 2IP) compared to F88A Y110H. However, no further attempts to mutate 3EO8 were 
pursued since all potential residues near the predicted position of 2IP were already mutated to 
smaller amino acids compared to the wild-type, but only ~20% fluorescence quenching was 
observed at ~10 mM 2IP. This finding indicated that the modified active sites of 3EO8 proteins 
cannot efficiently accommodate 2IP. Perhaps, thermodynamically favorable interactions were not 
established in the mutants. Specific orientations of the active site lid and loop may be required to 
accommodate 2IP. In contrast to IYD, the lid and loop of 3EO8 protrude away from the modelled 
position of 2IP and would not likely cover 2IP (Figure 5-7 B). Good affinity of 2IP to hhIYD (Kd 
= 67 µM) may in part be mediated by incorporation of the lid and loop of hhIYD. The lid of hhIYD 
may be partially formed upon binding of 2IP and cover the 2IP-FMN complex and therefore 
maintains 2IP in the active site. Partial lid formation can be determined by performing a limited 
proteolysis experiment to evaluate the dynamics of the protein structure.  
 Binding studies implied that the active site of 3EO8 was possibly not designed for any substrates 
as large as 2IP. However, this enzyme seems to share two common features with IYD and BluB. 
Inability of 3EO8 to catalyze NAD(P)H-dependent FMN reduction suggested that 3EO8 may 
require a specific reductase to transfer electrons from NAD(P)H to FMNox similar to that needed 
for BluB and IYD. A reductase, SsuE, was already identified for BluB while that of IYD is still 
unknown.15, 28, 83 Hence, dithionite has been used as an alternative reductant in most IYD analyses. 
The second BluB-, IYD- like feature of 3EO8 is the likely use of one-electron chemistry for 
catalysis as it is sensitive to molecular oxygen (Figure 5-14). This condition is consistent with 
hydrogen bonding to N5-FMN that is potentially established by a side chain Thr163 of 3EO8 
(Figure 5-8 A). Recovery of FMNox bound to 3EO8 in the presence of oxygen also confirmed that 




 Binding experiments indicated that BluB and 3EO8 do not have affinity for 2IP. Eight individual 
3EO8 mutants did not increase affinity with 2IP as no more than 20 % fluorescence quenching was 
observed. Mutant 5 (3EO8 F88A Y110S) appeared to have the best affinity with 2IP with ~20 % 
fluorescence quenching after titration of 2IP (~10 mM). Binding of 2IP may in part require proper 
orientation of the lid and loop as that appears in IYD. Sufficient space for 2IP alone may not be 
enough to improve the affinity for 2IP as this enzyme exhibits different orientations of the lid and 
loop from those of IYD. However, 3EO8 likely drives one-electron process as its FMNhq is able to 
be re-oxidized to FMNox in the presence of O2 indicating this enzyme is oxygen sentitive. Recovery 
of FMNox also indicated that activity of 3EO8 is different from BluB which fragments the FMNhq 
for a synthesis of the lower ligand of vitamin B12.28 Similar to BluB and IYD, 3EO8 may require 

















Chapter 6: Conclusions 
 The selected IYDs from an eukaryote (human IYD) and two prokaryotes (hhIYD and pfuIYD) 
demonstrated different binding selectivity but surprisingly similar catalytic specificity. Both hhIYD 
and pfuIYD share more binding promiscuity with 2IP compared to human IYD as indicated by 
their Kd values (Kd = 67 µM (hhIYD), 79 µM (pfuIYD) and 1,410 µM (human IYD)). The reasons 
for the different affinity of the three IYDs for 2IP are still unclear. However, significant differences 
in the affinity of hhIYD and human IYD for 2IP may be apparent from their crystal structures. 
Tight affinity of hhIYD for 2IP may be explained the presence of a pre-organized loop near the 
active site of hhIYD, which is not maintained in human IYD (Appendix Figure B2). However, high 
affinity of hhIYD and pfuIYD for 2IP does not increase their catalytic efficiency as shown by the 
kcat/Km values of 2IP and I-Tyr that remain within an order of magnitude of those of human IYD. 
Catalysis of all three IYDs is still very selective for iodotyrosines (I-Tyr and I2-Tyr) as evident by 
kcat/Km values for deiodination of iodotyrosines that are 4 – 5 orders of magnitude greater than those 
of 2IP.  
 hhIYD exhibits the least difference in affinity for I-Tyr and 2IP as shown by the only 8-fold 
difference in their Kd values. Initially, the zwitterion of I-Tyr was not thought to be necessary for 
binding or even for catalysis of hhIYD. Further binding studies of hhIYD with 2IP derivatives 
revealed that the phenolate anion of the ligand is key for affinity to hhIYD. More acidic phenolic 
protons lead to stronger affinity with hhIYD. However, high affinity for the active site does not 
ensure efficient catalysis as demonstrated by the lack of turnover of 2IPCN despite its affinity with 
hhIYD that rivals an equivalent affinity of I-Tyr. Tight binding to the active site is therefore not the 
only determinant for IYD catalysis.  
 Slow turnover of 2IP by hhIYD can be explained by crystallographic and redox studies. Similar 
to human IYD, the zwitterion of halotyrosines is also essential for hhIYD to stabilize one electron 
chemistry, which is key for efficient deiodination. Crystal structures of hhIYD demonstrated that 
coordination of I-Tyr can induce formation of an active site lid. The co-crystal of hhIYDI-Tyr 
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does not show hydrogen bonding from a side chain of Thr173 to N5-FMN, which potentially 
stabilizes a radical intermediate FMNsq. However, a switch from two- to one-electron chemistry 
was evident by detection of FMNsq during reduction of hhIYD in the presence of a substrate analog, 
F-Tyr.  
 A co-crystal structure of hhIYD2IP shows that 2IP aligns similar to the conformation of the 
aromatic ring of I-Tyr. However, 2IP is not able to trigger formation of the active site lid of hhIYD. 
It also lacks the ability to stabilize accumulation of FMNsq during reduction of hhIYD in the 
presence of 2IP. These results indicated that π-stacking interaction between 2IP and FMN together 
with close proximity of the reaction sites (C–I bond of 2IP and C4a–N5 FMN) are not sufficient 
for effective IYD catalysis. These observations explain the slow catalysis of hhIYD for 2IP despite 
its decent affinity. 
 Engineering of IYD was performed to increase the kcat/Km values for catalysis of iodophenols 
for bioremediation. Phyre2 provided a good model of hhIYD for engineering studies as indicated 
by superimposable structures of the predicted hhIYD in the absence of ligand and a crystal structure 
of hhIYDI-Tyr (RMSD of 1.374 Å for 367 Cα atom comparison of the Phyre2 model and PDB: 
5KO8). The selected residues for engineering would still be the best to change if the actual crystal 
structure were used for an engineering design as those residues of the hhIYD model are aligned 
with those of the crystal structure. However, modifications of hhIYD to increase affinity for 2IP 
(mutant A: A64F L107A), to stabilize the C-terminus of αC lid region (mutant B: S94D N96R 
S175H), and to introduce an attractive interaction between the active site lid and the carboxylate of 
2IPCOOH (mutant C: E91R) did not increase the catalytic efficiency for deiodination of 
iodophenols as evident by decrease in kcat/Km values for 2IP and 2IPCOOH by 3 – 16 fold compared 
to those of the wild-type. However, replacement of a repulsive interaction with 2IPCOOH by an 
attractive interaction (E91R) did significantly decrease the Km value by ~4 fold compared to that 
of the wild-type. The previous studies of Drosophila IYD showed in contrast that mutation of this 
85 
 
equivalent (E154Q) significantly increased the Km for deiodination of I2-Tyr which is likely 
because a favorable electrostatic interaction between Glu and the zwitterion of I2-Tyr was removed. 
Site-directed mutagenesis of hhIYD and Drosophila IYD both revealed that this substitution of Glu 
may help to optimize the Km value for deiodination of different non-physiological substrates. 
Hence, a site-saturation mutagenesis at this residue to fine-tune the Km values for deiodination of 
iodophenols is recommended for future study.  
 The hub enzyme with most structural similarity to IYD, 3EO8, was also selected to engineer for 
deiodination of iodophenols. Modifications were introduced to increase the volume of the active 
site, which was thought to be too small to accommodate of 2IP. However, none of the mutants 
exhibited a significant increase in affinity for 2IP compared to the wild-type. Differences in the 
orientation of the lid and loop of 3EO8 versus those of IYD (Figure 5-7) may explain the inability 
to accommodate 2IP despite the increased active site volume. The lid and loop of 3EO8 do not 
cover its active site in contrast to those of hhIYD. This observation suggested that placement of the 
lid and loop of hhIYD may be suitable for 2IP binding and also supported that its pre-organized 
loop may contribute to the greater affinity for 2IP compared to that of human IYD in which the 
equivalent loop is disordered.  
 Initial engineering studies of IYD and 3EO8 suggested that optimizing deiodinase activity for 
catalysis of the non-native substrates is not straightforward. Efficient IYD activity involves 
structural changes upon binding of the zwitterionic substrate to maintain its high substrate 
specificity. A computational design is a powerful tool for engineering catalysis as it can identify 
novel amino acid sequences and can predict various mutations that may induce cooperative for 
substrate binding and/or catalysis. An alternative directed evolution approach could explore huge 
sequence space in fine-tuning IYD catalysis for iodophenols. However, a fast and sensitive 
screening system for selection is necessary to test large numbers of the mutants. Identification of a 
specific reductase for reduction of IYD-bound FMN would enable a fast screening for IYD activity 
by monitoring the absorbance for depletion of NAD(P)H. Currently, finding good candidates for 
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engineering is also a key to success. Development of the sequence similarity network (SSN) is also 
a powerful tool to search for useful candidates for engineering as SSN allows analysis of huge 
native sequence assemblies that have been discovered to date. This method enhances the possibility 
to identify IYD variants with different catalytic specificity. For example, the nitro-FMN reductase 
superfamily was analyzed by Dr. Akiva (Dr. Babbit Lab, University of California at San Francisco) 
to generate the SSN. A couple of IYD homologs were selected from proteins that belong to a cluster 
of IYD enzymes by Dr. Janine Copp (University of British Columbia, Vancouver) and one of the 
selected homologs, an IYD from Thermotoga neopolitiana (tnIYD), was studied for deiodination 
rates of 2IP at 60 oC by Jamie Alley. The results showed that tnIYD exhibited ~ 5-fold higher kcat 
and ~2.5 fold higher kcat/Km compared to those of pfuIYD at the same temperature. These results 
suggested that tnIYD is another good candidate to improve deiodination rates for iodophenols. 
These various approaches demonstrate their own unique set of advantages and disadvantages for 
engineering studies. Integration of multiple approaches should increase our chances to enhance a 




















































Figure A3. Standards used to identify components of deiodination reactions by IYD. The following 
mixtures were incubated under the same condition containing 111 mM potassium phosphate pH 7.4 
(900 µl) with addition of 5% dithionite in 5% sodium bicarbonate (100 µl) to a final volume of 1 ml. 
The mixtures were then incubated at 25 oC for an indicated period of time followed by quenching 
with 88% formic acid (50 µl) except for (D) that was directly injected onto HPLC without addition 
of 88% formic acid to maintain pH of the mixture similar to that of elution buffer. Each mixture was 
subject to reverse phase HPLC using a flow rate 1 ml/min, solvent A: 0.44% aq. formic acid and 
solvent B: 0.44% formic acid in acetonitrile according to indicated gradients (A) 100 µM I-Tyr, 1 
µM hhIYD, 30 µM m-cresol, incubated for 15 mins, gradient: 0-5% B for 10 min, 5-60% B for 15 
min and a wash (60-95% B for 5 min and 95% B for 10 min); (B) 5 mM 2IP, 0 and 2.5 µM hhIYD 
(black and red lines), 30 mM m-cresol, incubated for 2 hours, gradient: 0-7% B for 10 min, 7-35% 
B for 15 min and a wash (35-95% B for 5 min and 95% B for 10 min); (C) 1 mM 2IPCOOH, 2.5 
µM hhIYD, 30 µM benzoic acid, incubated for 3 hours, gradient: 0-10% B for 5 min, 10-30% B for 
25 min and a wash (35-95% B for 5 min and 95% B for 10 min). 2IP has a phenol product 
contaminated (1.2 %). Contributions to product signals were subtracted prior to analysis.; (D) 0.8 
mM 4A2IP, 2 µM hhIYD, 30 µM m-cresol, incubated for 2 hours, solvent A: 10 mM ammonium 
formate, pH 6.8 and solvent B: acetonitrile, gradient: 0% B for 10 min, 0-30% B for 20 min and a 




























Figure A4. Standard curves for determination of a deiodinated product produced by IYD (A) Tyr 
(B) phenol (C) 4-hydroxybenzoate, COOHP (D) 4-aminophenol, 4AP (E) 4-hydroxybenzonitrile, 
CNP. Known concentrations of each deiodinated product were spiked into the reaction mixtures 
without its substrate and the mixtures were analyzed by HPLC. The ratios of AUC of the 
deiodinated product to AUC of IS were plotted against the known concentrations of spiked 
product. Each point represents an average of two individual measurements. Each indicated 
equation was determined from linear regression and used for calculation of each product 






Figure A5. SDS-PAGE gel of the purified pfuIYD K11R mutant. Lane 1 is marker with molecular 
weights of protein (kDa) indicated on the left. Lane 2 – 5 exhibited fractions containing an 
uninduced protein, induced protein, soluble fraction and insoluble fraction, respectively. Lane 6 is 














Figure A6. Steady-state kinetics of 125I-[I2-Tyr] turnover by IYD homologs. Initial rates of 
deiodination were determined by quantifying 125I- released by IYD. Each data point represents an 
average of two individual observations and error bars represent the standard deviations from the 
average. The kinetic parameters were determined from the best fit of data (solid lines) to the 
























Figure A7. Quenching of FMNox fluorescence upon ligand binding to pfuIYD at 25 oC and 60 oC. 
pfuIYD (2.5 µM) in 100 mM potassium phosphate, pH 6.9 were stirred at 25 oC for 30 min or 60 
oC for 10-15 min prior to addition of the indicated ligand. The Kd values derived from the best fit 








































Figure A8. Steady-state kinetics of I-Tyr, 2IP and 2IP derivatives by IYD. Initial rates of 
deiodination were determined by quantifying the deiodinated products after separation by reverse-
phase HPLC. Low solubility of 4A2IP ( 1mM) in 100 mM potassium phosphate, pH 7.4 limited 
the studies at substrate saturation. Hence, its kcat/Km was estimated from a Lineweaver-Burk plot at 
4A2IP concentrations of 0-0.8 mM. Each data point represents an average of three individual 
observations and error bars represent the standard deviations from the average except for (B) where 
the data points are from three independent determinations performed at different set of substrate 
concentrations. The kinetic parameters were determined from the best fit of data (solid lines) to the 



























Figure A9. HPLC chromatogram of deiodination of 2IPCN by hhIYD. A mixture of 2IPCN (10 
mM), m-cresol (30 µM) in 111 mM potassium phosphate buffer pH 7.4 (900 µl) together with (A) 
hhIYD (0 µM), (B) hhIYD (2.5 µM), (C) hhIYD (2.5 µM), standard 4-cyanophenol (10 µM) was 
incubated at 25 oC for 5 mins prior to addition of dithionite in 5% sodium bicarbonate solution (100 
µl) to the final volume of 1 ml. After 4 h, each mixture was quenched by addition of 88% formic 
acid (50 µl). The entire mixture (1050 µl) was subjected to reverse phase HPLC using solvent A: 
0.44% aq. formic acid and solvent B: 0.44% formic acid in acetonitrile. A product was separated 
using a gradient; 0-25 % B for 10 min, 25 % B for 10 min (0.8 ml/min) and a wash (25-60% B for 

















Figure A10. Chromatogram of 2IP incubated with free FMN. A mixture containing FMN (2.5 μM), 
2IP (5 mM), m-cresol (30 µM) in 111 mM potassium phosphate buffer (900 µl) was incubated at 
25 oC for 5 mins prior to addition of dithionite in 5% sodium bicarbonate solution (100 µl) to the 
final volume of 1 ml. The mixtures were continued with incubation at 25 oC for 0 h (black line) and 
2 h (red line) followed by quenching with 88% formic acid (50 µl) prior to analysis by HPLC. See 
Figure A3 for HPLC solvents and gradients used for analysis. 2IP has a phenol contaminated 





Figure A11. Chromatogram of 2BP turnover by hhIYD. A mixture containing hhIYD (0 μM, black 
line and 10 µM, red line), 2BP (2 mM), m-cresol (20 µM) in 111 mM potassium phosphate buffer 
(900 µl) was incubated at 25 oC for 5 mins prior to addition of dithionite in 5% sodium bicarbonate 
solution (100 µl) to the final volume of 1 ml. The mixtures were continued with incubation at 25 
oC for 4 h followed by quenching with 88% formic acid (50 µl). The entire mixture (1050 µl) was 
subjected to reverse phase HPLC (1 ml/min) using solvent A: 10 mM triethylamine acetate, pH 4.0 
and solvent B: acetonitrile. A product was separated using a gradient; 10 – 60 % B for 30 min, 60 
– 100 % B for 5 min and a wash (100% B for 10 min). 2-bromophenol (2BP) has a phenol 
contaminated (0.6%). No phenol produced more than a threshold of 5 nmol over 4 h indicating very 































Figure B1. Superposition of IYD structures. Overlay of the hhIYD structure (PDB: 5KO7, grey) 
with (A) mouse IYD (PDB: 3GB5, dark blue) (B) human IYD (PDB: 4TTB, orange) (C) hhIYDI-
Tyr (PDB: 5KO8, cyan) and (D) hhIYD2IP (PDB: 5KRD, green). FMNox, I-Tyr and 2IP are 





















Figure B2. Superimposition of the loop region in IYD homologs. The loop of hhIYD (PDB: 5KO7, 
grey) is exist while the equivalent loops of mouse IYD (PDB: 3GB5, dark blue) and human IYD 
(PDB: 4TTB, orange) are undetectable. Discontinuous ends are generated as indicated by (*). The 











Figure B3. UV spectrum monitoring reduction of FMN bound to hhIYD in the absence of ligand. 
FMNox (446 nm) is decreased upon reduction and no FMNsq accumulation was detected (590 nm). 
Solution contained xanthine (1 mM), methyl viologen (13 µM), hhIYD (20 µM), potassium 
phosphate (100 mM) pH 7.4, sodium chloride (500 mM) and glycerol (10% v/v). Reduction was 
initiated by addition of xanthine oxidase (140 µg/ml, final). The experiment was performed at pH 





Figure B4. Quenching of FMNox fluorescence upon ligand binding to hhIYD. hhIYD (2.5 µM) in 
100 mM potassium phosphate, pH 7.4 was stirred at 25 oC for 30 min prior to addition of the 
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Figure C1. Quenching of FMNox fluorescence upon ligand binding to hhIYD: wild type (black) 
and mutant A, hhIYD A64F L107A (red). hhIYD (2.5 µM) in 100 mM glycine-KOH and 114 mM 
KCl, pH 9.0 was stirred at 25 oC for 30 min prior to addition of the indicated ligand. The Kd values 














Figure C2. Steady-state kinetics of 2IP. Deiodination of 2IP by wild-type hhIYD (2.5 μM) (black), 
mutant A, hhIYD A64F L107A (2.5 μM) (red) and mutant B, hhIYD S94D N96R S175H (2.5 μM) 
(green). Initial rates of deiodination were determined by quantifying phenol product after separation 
by reverse-phase HPLC. Each data point represents a single observation. The kinetic parameters 












Figure C3. Steady-state kinetics of 2IPCOOH. Deiodination of 2IPCOOH by wild-type hhIYD 
(2.5 μM) (black), mutant A, hhIYD A64F L107A (2.5 μM) (red), mutant B, hhIYD S94D N96R 
S175H (2.5 μM) (green) and mutant C, hhIYD E91R (3.5 μM) (blue). Initial rates of deiodination 
were determined by quantifying 4-hydroxybenzoate product after separation by reverse-phase 
HPLC. Each data point represents a single observation. The kinetic parameters were determined 




















Figure C4. Steady-state kinetics of 2IPCOOH and I-Tyr by hhIYD mutants. Deiodination of (A) 
2IPCOOH by mutant C (hhIYD E91R) and (B) I-Tyr by mutant A hhIYD A64F L107A. Initial 
rates of deiodination were determined by quantifying the deiodinated product after separation by 
reverse-phase HPLC. Each data point represents an average of three individual observations and 
error bars represent the standard deviations from the average. The kinetic parameters were 

































Figure D1. Translated gene sequence of a pSpeedET vector containing a wild-type 3EO8 gene. 
The translated sequence includes the 3EO8 gene (accession YP_001089088.1) (codons in black), 
the N-terminal His6 (codons in red) and extra codons derived from the pSpeedET plasmid (codons 









Figure D2. Protein corresponding to the translated sequence containing 3EO8 gene shown in 
Figure D1. The expressed protein includes the 3EO8 protein (black) with His6 (red) and another 13 










































Figure D3. SDS-PAGE gels of purified BluB protein. Lane 1 is marker with molecular weights of 
protein (kDa) indicated on the left. Lane 2 – 5 exhibited fractions containing induced protein, 
insoluble proteins, soluble proteins and contaminated proteins of the flowthrough from Ni-NTA 
affinity column respectively. Lane 6 – 7 were from a step-wise washes from Ni-NTA purification 
with buffer containing 20 and 60 mM imidazole respectively. Lane 8 – 9 are purified BluB enzyme 

















Figure D4. SDS-PAGE gels of purified 3EO8 proteins. (A) wild-type (B) mutant 1 (F88A) (C) 
mutant 2 (F92A) (D) mutant 3 (F88A F92A) (E) mutant 4 (F88A Y110H) (F) mutant 5 (F88A 
Y110H S113) (G) mutant 6 (F88A Y110H K40A) (H) mutant 8 (F88A Y110S). Lane 1 is marker 
with molecular weights of protein (kDa) indicated on the left. Lane 2 – 5 exhibited fractions 
containing an uninduced protein, induced protein, insoluble proteins and soluble proteins, 
respectively. Lane 6 – 7 are purified 3EO8 after Ni-NTA affinity column and size-exclusion 




Figure D5. ITC binding measurement for titration of a ligand into BluB. ITC binding isotherm of 
(A) FMN (~70 µM) titrated into BluB solution (25 µM, 1.5 ml) and (B) 2IP (~ 1 mM) titrated into 
BluB-FMN solution (BluB = 70 µM, 1.5 ml; FMN = 140 µM). Assays were performed in buffer 
containing 10 mM Tris pH 8.0, 10 mM NaCl at 23°C. Data from a single experiment were fitted to 
a single-binding site model 32 using Origin ITC software (V. 5.0, Microcal Software Inc.) and the 
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- Introduction to chemistry: Holding help sessions for a group of 5 – 10 students at Johns Hopkins 
University.  
- Organic chemistry laboratory: Briefing laboratory procedures for a group of 10 – 15 students at 
Johns Hopkins University.  
 
Publications 
Nattha Ingavat, Jennifer M. Kavran, Zuodong Sun, Steven E. Rokita. Active site binding is not 
sufficient for reductive deiodination by iodotyrosine deiodinase. Biochemistry 2017, 56 (8), 1130 
– 1139. 
 
Acharavadee Pansanit, Nattha Ingavat, Thammarat Aree, Chulabhorn Mahidol, Somsak 
Ruchirawat, Prasat Kittakoop. Nitrone formation in phosphate buffer and aqueous solutions: novel 




Nattha Ingavat, Chulabhorn Mahidol, Somsak Ruchirawat, Prasat Kittakoop. Asperaculin A, a 
sesquiterpenoid from a Marine-derived fungus, Aspergillus aculeatus. J. Nat. 
Prod. 2011, 74(7), 1650 – 1652. 
 
Nattha Ingavat, Jeffrey Dobereiner, Suthep Wiyakrutta, Chulabhorn Mahidol, Somsak Ruchirawat, 
Prasat Kittakoop. Aspergillusol A, an α-glucosidase inhibitor from the marine-derived fungus 
Aspergillus aculeatus. J. Nat. Prod. 2009, 72(11), 2049 – 2052. 
 
Presentations 
- Poster presentation: 30th Anniversary Symposium of the Protein Society (2016), Hyatt Regency 
Baltimore, MD. Title “Active site binding is not sufficient for reductive deiodination by 
iodotyrosine deiodinase” 
- Poster presentation: 45th Mid-Atlantic Protein Crystallography Meeting (2015), Johns Hopkins 
University, Homewood Campus, Baltimore MD. Title “Engineering iodotyrosine deiodinase to 
broaden the substrate specificity” 
 
Honors and Awards 
- Full scholarship, Center of Excellence on Environmental Health, Toxicology and Management of 
Chemicals (ETM) and Chulabhorn Research Institute, June 2007 – August 2009 
- Certificates from Dr. Tab Nilanidhi Foundation, 2004 and 2007 
- Full scholarship, Faculty of Science, Kasetsart University May 2004 – May 2006 
 
 
